<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-376-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EVRA TRANSDERMAL PATCHES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ETHINYLESTRADIOL,NORELGESTROMIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.6,6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Topical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Transdermal patch
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Box
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LTS LOHMANN Therapie-Systeme" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LTS LOHMANN Therapie-Systeme
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GEDEON RICHTER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03AA13 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EVRA contains two types of sex hormones, a progestogen called norelgestromin and an oestrogen called ethinyl estradiol.</p><p>&nbsp;</p><p>Because it contains two hormones, EVRA is called a &lsquo;combined hormonal contraceptive&rsquo;.</p><p>&nbsp;</p><p>It is used to prevent pregnancy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EVRA&reg; is contraindicated for concomitant use<br />with the medicinal products containing<br />ombitasvir/ paritaprevir/ ritonavir, and dasabuvir,<br />glecaprevir/ pibrentasvir and<br />sofosbuvir/velpatasvir/ voxilaprevir.</p><p><strong>General notes</strong></p><p>Before you start using EVRA you should read the information on blood clots in section&nbsp;2. It is particularly important to read the symptoms of a blood clot - see section&nbsp;2 &ldquo;Blood clots&rdquo;.</p><p>&nbsp;</p><p><strong>When you should not use EVRA</strong></p><p>You should not use EVRA if you have any of the conditions listed below. If you do have any of the conditions listed below, you must tell your doctor. Your doctor will discuss with you what other form of birth control would be more appropriate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have (or have ever had) a blood clot in a blood vessel of your legs (deep vein thrombosis, DVT), your lungs (pulmonary embolus, PE) or other organs;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know you have a disorder affecting your blood clotting - for instance, protein&nbsp;C deficiency, protein&nbsp;S deficiency, antithrombin‑III deficiency, Factor&nbsp;V&nbsp;Leiden or antiphospholipid antibodies;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you need an operation or if you are off your feet for a long time (see section &lsquo;Blood clots )&rsquo;;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had a heart attack or a stroke;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have (or have ever had) angina pectoris (a condition that causes severe chest pain and may be a first sign of a heart attack) or transient ischaemic attack (TIA &ndash; temporary stroke symptoms);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a disease that may increase your risk of a clot in the arteries:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe diabetes with blood vessel damage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a very high level of fat in the blood (cholesterol or triglycerides)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a condition known as hyperhomocysteinaemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have (or have ever had) a type of migraine called &lsquo;migraine with aura&rsquo;;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to norelgestromin, ethinyl estradiol or any of the other ingredients of this medicine (listed in section&nbsp;6);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever been told you might have breast cancer or cancer of the womb, cervix or vagina;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had liver tumours or a liver disease because of which your liver does not function properly;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have unexplained vaginal bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have hepatitis C and are taking the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir (see also in section &ldquo;Other medicines and EVRA&rdquo;</p><p>Do not use this medicine if any of the above applies to you. If you are not sure, talk to your doctor, pharmacist or nurse before using this medicine.</p><p><strong>When to take special care with EVRA</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>When should you contact your doctor?</p><p><u>&nbsp;</u></p><p><u>Seek urgent medical attention</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you notice possible signs of a blood clot that may mean you are suffering from a blood clot in the leg (i.e.&nbsp;deep vein thrombosis), a blood clot in the lung (i.e.&nbsp;pulmonary embolism), a heart attack or a stroke (see &lsquo;Blood clot [thrombosis] section below).</p><p>&nbsp;</p><p>For a description of the symptoms of these serious side effects please go to &ldquo;How to recognise a blood clot&rdquo;.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Warnings<br />During clinical trials with patients treated for<br />hepatitis C virus infections (HCV) with the<br />medicinal products containing<br />ombitasvir/paritaprevir/ritonavir and dasabuvir<br />with or without ribavirin, transaminase (ALT)<br />elevations higher than 5 times the upper limit of<br />normal (ULN) occurred significantly more<br />frequent in women using ethinylestradiolcontaining<br />medications such as combined<br />hormonal contraceptives (CHCs). ALT elevations<br />have also been observed with HCV anti-viral<br />medicinal products containing glecaprevir/<br />pibrentasvir and sofosbuvir/ velpatasvir/<br />voxilaprevir.</p><p>Before using this medicine, you will need to see your doctor for a medical check‑up.</p><p>&nbsp;</p><p><strong>Tell your doctor if any of the following conditions apply to you.</strong></p><p>&nbsp;</p><p>If the condition develops, or gets worse while you are using EVRA, you must tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have Crohn&rsquo;s disease or ulcerative colitis (chronic inflammatory bowel disease);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have SLE (systemic lupus erythematosus; a disease affecting your natural defence system);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have haemolytic uraemic syndrome (HUS - a disorder of blood clotting causing failure of the kidneys);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have sickle cell anaemia (an inherited disease of the red blood cells);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have elevated levels of fat in the blood (hypertriglyceridaemia) or a positive family history for this condition. Hypertriglyceridaemia has been associated with an increased risk of developing pancreatitis (inflammation of the pancreas);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you need an operation, or you are off your feet for a long time (see in section&nbsp;2 &lsquo;Blood clots&rsquo;);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have just given birth you are at an increased risk of blood clots. You should ask your doctor how soon after delivery you can start taking EVRA;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an inflammation in the veins under the skin (superficial thrombophlebitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have varicose veins.</p><p>&nbsp;</p><p><strong>BLOOD CLOTS</strong></p><p>&nbsp;</p><p>Using a combined hormonal contraceptive such as EVRA increases your risk of developing a blood clot compared with not using one. In rare cases a blood clot can block blood vessels and cause serious problems.</p><p>&nbsp;</p><p>Blood clots can develop</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in veins (referred to as a &lsquo;venous thrombosis&rsquo;, &lsquo;venous thromboembolism&rsquo; or VTE)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the arteries (referred to as an &lsquo;arterial thrombosis&rsquo;, &lsquo;arterial thromboembolism&rsquo; or ATE).</p><p>&nbsp;</p><p>Recovery from blood clots is not always complete. Rarely, there may be serious lasting effects or, very rarely, they may be fatal.</p><p>&nbsp;</p><p><strong>It is important to remember that the overall risk of a harmful blood clot due to EVRA is small.</strong></p><p>&nbsp;</p><p><strong>HOW TO RECOGNISE A BLOOD CLOT</strong></p><p>&nbsp;</p><p>Seek urgent medical attention if you notice any of the following signs or symptoms.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>Are you experiencing any of these signs?</p></td><td style="vertical-align:top"><p>What are you possibly suffering from?</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of one leg or along a vein in the leg or foot especially when accompanied by:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or tenderness in the leg which may be felt only when standing or walking;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased warmth in the affected leg;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in colour of the skin on the leg e.g.&nbsp;turning pale, red or blue.</p></td><td style="vertical-align:top"><p>Deep vein thrombosis</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden unexplained breathlessness or rapid breathing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden cough without an obvious cause, which may bring up blood;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sharp chest pain which may increase with deep breathing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe light headedness or dizziness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid or irregular heartbeat;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe pain in your stomach.</p><p>&nbsp;</p><p>If you are unsure, talk to a doctor as some of these symptoms such as coughing or being short of breath may be mistaken for a milder condition such as a respiratory tract infection (e.g.&nbsp;a &lsquo;common cold&rsquo;).</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p></td></tr><tr><td style="vertical-align:top"><p>Symptoms most commonly occur in one eye:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immediate loss of vision or;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painless blurring of vision which can progress to loss of vision.</p></td><td style="vertical-align:top"><p>Retinal vein thrombosis (blood clot in the eye)</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain, discomfort, pressure, heaviness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of squeezing or fullness in the chest, arm or below the breastbone;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fullness, indigestion or choking feeling;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper body discomfort radiating to the back, jaw, throat, arm and stomach;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating, nausea, vomiting or dizziness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; extreme weakness, anxiety, or shortness of breath;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid or irregular heartbeats.</p></td><td style="vertical-align:top"><p>Heart attack</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden weakness or numbness of the face, arm or leg, especially on one side of the body;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden confusion, trouble speaking or understanding;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden trouble seeing in one or both eyes;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden trouble walking, dizziness, loss of balance or coordination;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden, severe or prolonged headache with no known cause;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of consciousness or fainting with or without seizure.</p><p>&nbsp;</p><p>Sometimes the symptoms of stroke can be brief with an almost immediate and full recovery, but you should still seek urgent medical attention as you may be at risk of another stroke.</p></td><td style="vertical-align:top"><p>Stroke</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling and slight blue discolouration of an extremity;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe pain in your stomach (acute abdomen).</p></td><td style="vertical-align:top"><p>Blood clots blocking other blood vessels</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>BLOOD CLOTS IN A VEIN</strong></p><p><strong>&nbsp;</strong></p><p><strong>What can happen if a blood clot forms in a vein?</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The use of combined hormonal contraceptives has been connected with an increase in the risk of blood clots in the vein (venous thrombosis). However, these side effects are rare. Most frequently, they occur in the first year of use of a combined hormonal contraceptive.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If a blood clot forms in a vein in the leg or foot it can cause a deep vein thrombosis (DVT).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If a blood clot travels from the leg and lodges in the lung it can cause a pulmonary embolism.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rarely a clot may form in a vein in another organ such as the eye (retinal vein thrombosis).</p><p>&nbsp;</p><p><strong>When is the risk of developing a blood clot in a vein highest?</strong></p><p>The risk of developing a blood clot in a vein is highest during the first year of taking a combined hormonal contraceptive for the first time. The risk may also be higher if you restart taking a combined hormonal contraceptive (the same product or a different product) after a break of 4&nbsp;weeks or more.</p><p>&nbsp;</p><p>After the first year, the risk gets smaller but is always slightly higher than if you were not using a combined hormonal contraceptive.</p><p>&nbsp;</p><p>When you stop EVRA your risk of a blood clot returns to normal within a few weeks.</p><p>&nbsp;</p><p><strong>What is the risk of developing a blood clot?</strong></p><p>The risk depends on your natural risk of VTE and the type of combined hormonal contraceptive you are taking.</p><p>&nbsp;</p><p>The overall risk of a blood clot in the leg or lung (DVT or PE) with EVRA is small.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Out of 10,000 women who are not using any combined hormonal contraceptive and are not pregnant, about 2 will develop a blood clot in a year.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Out of 10,000&nbsp;women who are using a combined hormonal contraceptive that contains levonorgestrel, norethisterone, or norgestimate about 5‑7 will develop a blood clot in a year.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Out of 10,000&nbsp;women who are using a combined hormonal contraceptive that contains etonorgestrel or norelgestromin such as EVRA between about 6 and 12&nbsp;women will develop a blood clot in a year.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The risk of having a blood clot will vary according to your personal medical history (see &ldquo;Factors that increase your risk of a blood clot&rdquo; below).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Risk of developing a blood clot in a year</p></td></tr><tr><td style="vertical-align:top"><p>Women who are <strong>not using</strong> a combined hormonal pill/patch/ring and are not pregnant</p></td><td style="vertical-align:top"><p>About 2 out of 10,000&nbsp;women</p></td></tr><tr><td style="vertical-align:top"><p>Women using a combined hormonal contraceptive pill containing <strong>levonorgestrel, norethisterone or norgestimate</strong></p></td><td style="vertical-align:top"><p>About 5‑7 out of 10,000&nbsp;women</p></td></tr><tr><td style="vertical-align:top"><p>Women using EVRA</p></td><td style="vertical-align:top"><p>About 6‑12 out of 10,000&nbsp;women</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Factors that increase your risk of a blood clot in a vein</strong></p><p>The risk of a blood clot with EVRA is small but some conditions will increase the risk. Your risk is higher:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are very overweight (body mass index or BMI over 30&nbsp;kg/m<sup>2</sup>);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if one of your immediate family has had a blood clot in the leg, lung or other organ at a young age (e.g.&nbsp;below the age of about 50). In this case you could have a hereditary blood clotting disorder;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you need to have an operation, or if you are off your feet for a long time because of an injury or illness, or you have your leg in a cast. The use of EVRA may need to be stopped several weeks before surgery or while you are less mobile. If you need to stop EVRA ask your doctor when you can start using it again;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as you get older (particularly above about 35&nbsp;years);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you gave birth less than a few weeks ago.</p><p>&nbsp;</p><p>The risk of developing a blood clot increases the more conditions you have.</p><p>&nbsp;</p><p>Air travel (&gt;&nbsp;4&nbsp;hours) may temporarily increase your risk of a blood clot, particularly if you have some of the other factors listed.</p><p>&nbsp;</p><p>It is important to tell your doctor if any of these conditions apply to you, even if you are unsure. Your doctor may decide that EVRA needs to be stopped.</p><p>&nbsp;</p><p>If any of the above conditions change while you are using EVRA, for example a close family member experiences a thrombosis for no known reason; or you gain a lot of weight, tell your doctor.</p><p>&nbsp;</p><p><strong>BLOOD CLOTS IN AN ARTERY</strong></p><p>&nbsp;</p><p><strong>What can happen if a blood clot forms in an artery?</strong></p><p>Like a blood clot in a vein, a clot in an artery can cause serious problems. For example, it can cause a heart attack or a stroke.</p><p>&nbsp;</p><p><strong>Factors that increase your risk of a blood clot in an artery</strong></p><p>It is important to note that the risk of a heart attack or stroke from using EVRA is very small but can increase:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with increasing age (beyond about 35&nbsp;years);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you smoke</strong>. When using a combined hormonal contraceptive like EVRA you are advised to stop smoking. If you are unable to stop smoking and are older than 35 your doctor may advise you to use a different type of contraceptive;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are overweight;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have high blood pressure;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if a member of your immediate family has had a heart attack or stroke at a young age (less then about 50). In this case you could also have a higher risk of having a heart attack or stroke;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you, or someone in your immediate family, have a high level of fat in the blood (cholesterol or triglycerides);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get migraines, especially migraines with aura;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a problem with your heart (valve disorder, disturbance of the rhythm called atrial fibrillation);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes.</p><p>&nbsp;</p><p>If you have more than one of these conditions or if any of them are particularly severe the risk of developing a blood clot may be increased even more.</p><p>If any of the above conditions change while you are using EVRA, for example you start smoking, a close family member experiences a thrombosis for no known reason; or you gain a lot of weight, tell your doctor.</p><p><strong>Psychiatric disorders</strong></p><p>Some women using hormonal contraceptives including EVRA have reported depression or depressed mood. Depression can be serious and may sometimes lead to suicidal thoughts. If you experience mood changes and depressive symptoms contact your doctor for further medical advice as soon as possible.</p><p>Additionally, talk to your doctor, pharmacist or nurse before using EVRA if you have any of the following or they happen or get worse while using EVRA:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You think you might be pregnant;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have headaches that get worse or happen more often;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You weigh 90&nbsp;kg (which is 14&nbsp;stone&nbsp;2&nbsp;lb) or more;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have high blood pressure or your blood pressure gets higher;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have gallbladder disease including gallstones or inflammation of the gallbladder;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a blood problem called porphyria;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a problem of the nervous system involving sudden movements of the body called &lsquo;Sydenham&rsquo;s chorea&rsquo;;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You had a skin rash with blisters during pregnancy (called &lsquo;herpes gestationis&rsquo;);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a hearing loss;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have diabetes;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have depression;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have epilepsy or any other problem that can cause fits (convulsions);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have liver problems including yellowing of the skin and whites of the eye (jaundice);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have or have had &lsquo;pregnancy spots&rsquo;. These are yellowish‑brown patches or spots, especially on your face (called &lsquo;chloasma&rsquo;). These spots may not go away completely, even after you stop using EVRA. Protect your skin from sunlight or ultraviolet radiation. This may help prevent you from getting these spots or help prevent them from getting worse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have kidney problems.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using EVRA.</p><p>&nbsp;</p><p><strong>Sexually transmitted disease</strong></p><p>This medicine will not protect you against HIV infection (AIDS) or any other sexually transmitted disease. These include chlamydia, genital herpes, genital warts, gonorrhoea, hepatitis&nbsp;B, syphilis. Always use condoms to protect yourself from these diseases.</p><p>&nbsp;</p><p><strong>Medical tests</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you need a blood or urine test, tell your doctor or the laboratory staff that you are taking EVRA, because hormonal contraceptives can affect the results of some tests.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>EVRA has not been studied in children and adolescents under 18&nbsp;years of age. EVRA must not be used in children and adolescents who have not yet had their first menstrual period.</p><p>&nbsp;</p><p><strong>Other medicines and EVRA</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.</p><p>Do not use EVRA if you have Hepatitis C and are taking the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir as this may cause increases in liver function blood test 7 results (increase in ALT liver enzyme). Your doctor will prescribe another type of contraceptive prior to start of the treatment with these medicinal products. EVRA can be restarted approximately 2 weeks after completion of this treatment. See section &ldquo;When you should not use EVRA&rdquo;.</p><p>Certain medicines and herbal therapies may stop EVRA from working properly. If this happens you could get pregnant, or may experience unexpected bleeding.</p><p>These include medicines used for the treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antiretroviral medicines used to treat HIV/AIDS and Hepatitis C virus infections (so-called protease inhibitors and non‑nucleoside reverse transcriptase inhibitors such ritonavir, nevirapine, efavirenz))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for infection (such as rifampicin and griseofulvin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti‑seizure medicines (such as barbiturates, topiramate, phenytoin, carbamazepine, primidone, oxcarbazepine, and felbamate)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bosentan (a medicine for high blood pressure in the blood vessels in the lungs)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (an herbal therapy used for depression)</p><p>&nbsp;</p><p>If you take any of these medicines, you may need to use another method of birth control (such as a condom, diaphragm or foam). The interfering effect of some of these medicines can last for up to 28&nbsp;days after you have stopped taking them. Talk to your doctor or pharmacist about using another method of birth control if you use EVRA and any of the above medicines concomitantly.</p><p>&nbsp;</p><p>EVRA may make some other medicines less effective, such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines containing ciclosporin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lamotrigine used for epilepsy [This can increase the risk of fits (seizures)].</p><p>&nbsp;</p><p>Your doctor may need to adjust the dose of the other medicine. Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you are pregnant or think you may be pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stop using this medicine right away if you become pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you are breast‑feeding or planning to breast‑feed.</p><p>&nbsp;</p><p>If you think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You can drive or use machines while using this medicine.</p><p>&nbsp;</p><p><strong>Risks of using combined hormonal contraceptives</strong></p><p>The following information is based on information about combined birth control pills. As the EVRA transdermal patch contains similar hormones to those used in combined birth control pills, it is likely to have the same risks. All combined birth control pills have risks, which may lead to disability or death.</p><p>&nbsp;</p><p>It has not been shown that a transdermal patch like EVRA is safer than a combined birth control pill taken by mouth.</p><p>&nbsp;</p><p><strong>Combined</strong><strong> hormonal contraceptives and cancer</strong></p><p>&nbsp;</p><p><strong>Cervical cancer</strong></p><p>Cervical cancer has been found more often in women taking combined hormonal contraceptives. However, this may be due to other causes including sexually‑transmitted disease.</p><p>&nbsp;</p><p><strong>Breast cancer</strong></p><p>Breast cancer has been found more often in women who take combined hormonal contraceptives. However, it is possible that the combined hormonal contraceptive is not the cause of more women having breast cancer. It may be that women taking the combined hormonal contraceptive are examined more often. This might mean that there is a better chance of the breast cancer being noticed. The increased risk gradually goes down after stopping the combined hormonal contraceptive. After 10&nbsp;years, the risk is the same as for people who have never used the combined hormonal contraceptive.</p><p>&nbsp;</p><p><strong>Liver cancer</strong></p><p>In rare cases, liver tumours which are not cancer have been found in women taking combined hormonal contraceptives. Even more rarely, liver tumours which are cancer have been found. This can cause bleeding inside the body with very bad pain in the stomach area. <strong>If this happens to you, talk to your doctor immediately.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you do not, you may increase your risk of getting pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check with your doctor or pharmacist if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always keep non‑hormonal contraceptives (such as condoms, foam or sponge) as a back‑up in case you make a mistake when using the patch.</p><p>&nbsp;</p><p><strong>How many patches to use</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weeks&nbsp;1, 2 &amp; 3: &nbsp; Put on one patch and leave it on for exactly seven days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;4: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do <strong>not</strong> put on a patch this week.</p><p><u>&nbsp;</u></p><p><strong>If you have not used a hormonal contraceptive during your previous cycle</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may start this medicine on the first day of your next period.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If one or more days have elapsed since the start of your period, talk to your doctor about temporarily using a non‑hormonal contraceptive.</p><p><u>&nbsp;</u></p><p><strong>If you switch from the oral contraceptive pill to EVRA</strong></p><p>If you are switching from an oral contraceptive pill to this medicine:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wait until you get your menstrual period.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put on your first patch during the first 24&nbsp;hours of your period.</p><p>&nbsp;</p><p>If the patch is applied after Day&nbsp;1 of your period, you should:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use a non‑hormonal contraceptive until Day&nbsp;8 when you change your patch.</p><p>&nbsp;</p><p>If you do not get your period within 5&nbsp;days of taking the last contraceptive pill, check with your doctor before starting this medicine.</p><p>&nbsp;</p><p><strong>If you switch from the progestogen-only pill, an implant or an injectable to EVRA</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may start this medicine any day after stopping the progestogen‑only pill or on the day of removal of an implant or when the next injection would be due.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The first day after stopping the progestogen‑only pill, removing the implant or when your next injection would be due, put on a patch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use a non‑hormonal contraceptive until Day&nbsp;8, when you change your patch.</p><p>&nbsp;</p><p><strong>After miscarriage or abortion <em>before</em> 20&nbsp;weeks of pregnancy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may start this medicine right away.</p><p>&nbsp;</p><p>If one or more days have elapsed since your miscarriage or abortion when you start this medicine, talk to your doctor about temporarily using a non‑hormonal contraceptive.</p><p>&nbsp;</p><p><strong>After miscarriage or abortion <em>after</em> 20&nbsp;weeks of pregnancy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor.</p><p>&nbsp;</p><p>You may start this medicine on Day&nbsp;21 following the abortion or miscarriage, or on the first day of your next period, whichever comes first.</p><p>&nbsp;</p><p><strong>After delivery</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you&rsquo;ve had a baby and are not breast‑feeding, you should not start using this medicine sooner than 4&nbsp;weeks after delivery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you start more than 4&nbsp;weeks after delivery, use another non‑hormonal contraceptive in addition to this medicine for the first 7&nbsp;days.</p><p>&nbsp;</p><p>If you&rsquo;ve had sex since delivery of your baby, wait for your first period or see your doctor to make sure you are not pregnant before starting this medicine.</p><p>&nbsp;</p><p><strong>If you are breast‑feeding</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you are breast‑feeding or planning to breast‑feed (see also section&nbsp;2 Pregnancy and breast‑feeding).</p><p><u>&nbsp;</u></p><p><strong>Important information to follow when using the patch</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change EVRA on the same day of each week. This is because it is designed to work over 7&nbsp;days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Never go without wearing a patch for more than 7&nbsp;days in a row.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only wear one patch at a time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not cut or tamper with the patch in any way.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not put the patch on skin that is red, irritated or cut.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To work properly the patch must stick firmly to your skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press the patch down firmly until the edges stick well.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use creams, oils, lotions, powder or makeup on the skin where you are placing a patch or near a patch you are wearing. This may make the patch come loose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not put a new patch on the same area of skin as the old patch. If you do you are more likely to cause irritation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check each day to make sure the patch has not fallen off.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep using the patches even if you do not have sex very often.</p><p><img alt="" width="192" height="620" src="data:image/png;base64,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" /><img alt="" width="212" height="791" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><strong>How to use the patch:</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>If this is the first time you are using EVRA, wait until the day you get your menstrual period.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Apply your first patch during the first 24&nbsp;hours of your period</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the patch is put on after the first day of your period, use a non‑hormonal contraceptive until Day&nbsp;8, when you change your patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The day you apply your first patch will be Day&nbsp;1. Your &ldquo;Patch Change Day&rdquo; will be on this day of the week every week.</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Choose a place on your body to put the patch.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always put your patch on clean, dry, hairless skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put it on the buttock, abdomen, upper outer arm or upper back - places where it won&rsquo;t be rubbed by tight clothing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Never put the patch on your breasts</strong>.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Using your fingers, open the foil sachet.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open it by tearing it along the edge (do not use scissors)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Firmly grasp a corner of the patch and gently take it from the foil sachet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is a clear protective covering on the patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Sometimes patches can stick to the inside of the sachet &ndash; be careful not to accidentally remove the clear covering as you remove the patch</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then peel away half of the clear protective covering (see picture). Try not to touch the sticky surface.</p><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Put the patch on your skin.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then take off the other half of the covering</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press down firmly on the patch with the palm of your hand for 10&nbsp;seconds</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure that the edges stick well.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td><td style="vertical-align:top"><p>Wear the patch for 7&nbsp;days (one week).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On the first &ldquo;Patch Change Day&rdquo;, Day&nbsp;8, take off the used patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put on a new patch immediately.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On Day&nbsp;15 (Week&nbsp;3), take off the used patch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put on another new one.</p><p>&nbsp;</p><p>This makes a total of three weeks with the patches.</p><p>&nbsp;</p><p><strong>To help stop irritation, do not put the new patch on exactly the same area of your skin as your last patch</strong>.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Do not wear a patch on Week&nbsp;4 (Day&nbsp;22 through Day&nbsp;28).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>You should have your period during this time</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During this week you are protected from getting pregnant only if you start your next patch on time.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td><td style="vertical-align:top"><p>For your next four week cycle.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put on a new patch on your normal &ldquo;Patch Change Day&rdquo;, the day after Day&nbsp;28</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do this</strong> <strong>no matter when your period begins or ends</strong>.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>If you want to change your &ldquo;Patch Change Day&rdquo; to a different day of the week talk to your doctor. You will need to complete the current cycle and remove the third patch on the correct day. During Week&nbsp;4, you may pick a new Change Day and apply the first patch on that day. You should never go more than 7&nbsp;days in a row without wearing a patch.</p><p>&nbsp;</p><p>If you want to delay your period, apply a patch at the beginning of Week&nbsp;4 (Day&nbsp;22) instead of not wearing a patch on Week&nbsp;4. You may experience light or breakthrough bleeding. Do not wear more than 6&nbsp;patches (so not more than 6&nbsp;weeks) in a row. When you have worn 6&nbsp;patches in a row (so for 6&nbsp;consecutive weeks), do not put on a patch in week&nbsp;7. After 7&nbsp;days of not wearing a patch, apply a new patch and restart the cycle using this as Day&nbsp;1. Talk with your doctor before deciding to delay your period.</p><p>&nbsp;</p><p><strong>Everyday activities while using the patches</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Normal activities such as having a bath or shower, using a sauna and exercising should not affect how well the patch works.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patch is designed to stay in place during these types of activities.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; However, you should check that the patch has not fallen off after doing these activities.</p><p>&nbsp;</p><p><strong>If you need to place the patch on a new area on your body on a day other than your &ldquo;Patch Change Day&rdquo;</strong></p><p>If the patch causes irritation or you become uncomfortable wearing it:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take it off and replace it with a new patch in a different place on your body until your next &ldquo;Patch Change Day&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may only use one patch at a time.</p><p>&nbsp;</p><p><strong>If you have trouble remembering to change your patch</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor, pharmacist or nurse. He/she may be able to<strong> </strong>make patch changing easier for you. He/she may also talk about whether you need to use another method of contraception.</p><p>&nbsp;</p><p><strong>If your patch becomes loose, lifts at the edges or falls off</strong></p><p>&nbsp;</p><p><strong>For less than one day</strong> (up to 24&nbsp;hours):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Try to put it on again or put on a new patch immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back‑up contraception is not needed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your &ldquo;Patch Change Day&rdquo; should remain the same.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not try to put a patch back on if:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is no longer sticky</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it has become stuck to itself or another surface</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it has other material stuck to it</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is the second time it has become loose or has fallen off.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use tapes or wrapping to keep the patch in place.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you cannot get a patch back on, put on a new patch immediately.</p><p>&nbsp;</p><p><strong>For more than one day </strong>(24&nbsp;hours or more)<strong> </strong>or if you are not sure for how long:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Start a new four week cycle immediately by putting on a new patch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You now have a new Day&nbsp;1 and a new &ldquo;Patch Change Day&rdquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must use non‑hormonal contraception as back up for the first week of your new cycle.</p><p>&nbsp;</p><p>You may get pregnant if you do not follow these instructions.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to change your patch</strong></p><p>&nbsp;</p><p><strong>At the start of any patch cycle (Week&nbsp;1 (Day&nbsp;1)):</strong></p><p>If you forget to put on your patch, you may be at particularly high risk of becoming pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must use non‑hormonal contraception as back up for one week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put on the first patch of your new cycle as soon as you remember.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You now have a new &ldquo;Patch Change Day&rdquo; and new Day&nbsp;1.</p><p>&nbsp;</p><p><strong>In the middle of your patch cycle</strong> <strong>(Week&nbsp;2 or 3):</strong></p><p>If you forget to change your patch for one or two days<strong> </strong>(up to 48&nbsp;hours):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must put on a new patch as soon as you remember.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put on your next patch on your normal &ldquo;Patch Change Day&rdquo;.</p><p>&nbsp;</p><p>No back up contraception is needed.</p><p>&nbsp;</p><p><strong>For more than 2&nbsp;days </strong>(48&nbsp;hours or more)<strong>:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to change your patch for more than 2&nbsp;days, you may become pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must start a new four week cycle as soon as you remember by putting on a new patch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You now have a different &ldquo;Patch Change Day&rdquo; and a new Day&nbsp;1.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must use back‑up contraception for the first week of your new cycle.</p><p>&nbsp;</p><p><strong>At the end of your patch cycle (Week&nbsp;4):</strong></p><p>If you forget to take off your patch:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take it off as soon as you remember.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Start your next cycle on your normal &ldquo;Patch Change Day&rdquo;, the day after Day&nbsp;28.</p><p>&nbsp;</p><p>No back‑up contraception is needed.</p><p>&nbsp;</p><p><strong>If you have absent or irregular bleeding with EVRA</strong></p><p>This medicine may cause unexpected vaginal bleeding or spotting during the weeks when you are wearing the patch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This usually stops after the first few cycles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mistakes in using your patches can also cause spotting and light bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continue using this medicine and if the bleeding lasts more than the first three cycles, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>If you do not get your period during the EVRA<strong> </strong>patch‑free week (Week&nbsp;4), you should still use a new patch on your usual &ldquo;Patch Change Day&rdquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been using this medicine correctly and you do not have a period, this does not necessarily mean that you are pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; However, if you miss two periods in a row, talk to your doctor or pharmacist as you may<strong> </strong>be pregnant.</p><p>&nbsp;</p><p><strong>If you use more EVRA than you should (more than one EVRA patch at any one time)</strong></p><p>Take the patches off and talk to a doctor immediately.</p><p>&nbsp;</p><p>Using too many patches may cause you to have the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea) and being sick (vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding from the vagina.</p><p>&nbsp;</p><p><strong>If you stop using EVRA</strong></p><p>You may get irregular, little or no menstruation. This usually happens in the first 3&nbsp;months and especially if your periods were not regular before you started using this medicine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get any side effect, particularly if severe and persistent, or have any change to your health that you think may be due to EVRA, please talk to your doctor.</p><p>&nbsp;</p><p>An increased risk of blood clots in your veins [venous thromboembolism (VTE)] or blood clots in your arteries [arterial thromboembolism (ATE)] is present for all women taking combined hormonal contraceptives. For more detailed information on the different risks from taking combined hormonal contraceptives please see section&nbsp;2 &ldquo;What you need to know before you use EVRA&rdquo;.</p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10&nbsp;women):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast tenderness.</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10&nbsp;women):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal yeast infection, sometimes called thrush</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mood problems such as depression, change in mood or mood swings, anxiety, crying</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach ache or bloating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting or diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acne, skin rash, skin itching or skin irritation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle spasms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast problems such as pain, enlargement or lumps in the breast</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in menstrual bleeding pattern, uterine cramps, painful periods, vaginal discharge</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems where the patch has been on the skin such as redness, irritation, itching or rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling tired or generally unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain.</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100&nbsp;women):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction, hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling due to water retention in the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High levels of fats in the blood (such as cholesterol or triglycerides)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Less interest in sex</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eczema, redness of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal breast milk production</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Premenstrual syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal dryness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other problems where the patch has been on the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure or rise in blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensitivity to sunlight.</p><p>&nbsp;</p><p><strong>Rare side effects (may affect up to 1 in 1,000&nbsp;women):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Harmful blood clots in a vein or artery for example:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in a leg or foot (i.e.&nbsp;DVT)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in a lung (i.e.&nbsp;PE)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mini‑stroke or temporary stroke‑like symptoms, known as a transient ischaemic attack (TIA)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots in the liver, stomach/intestine, kidneys or eye.</p><p>The chance of having a blood clot may be higher if you have any other conditions that increase this risk (See section&nbsp;2 for more information on the conditions that increase risk for blood clots and the symptoms of a blood clot).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast, cervical or liver cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems where the patch has been on the skin such as skin rash with blisters or ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non‑cancerous (benign) tumours in your breast or liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fibroids in the womb (uterus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anger or feeling frustrated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased interest in sex</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems when wearing contact lenses</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden sharp increase in blood pressure (hypertensive crisis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the gall bladder or colon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal cells in your cervix</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brown spots or patches on the face</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gallstones or blockage of the bile duct</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of the skin and whites of the eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal blood sugar or insulin levels</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;A severe allergic reaction that may include swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash with tender red nodules on the shins and legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Scaly, flaky, itchy and red skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suppressed lactation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal discharge</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid retention in legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid retention</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling in the arms, hands, legs or feet.</p><p>&nbsp;</p><p><strong>If you have an upset stomach</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The amount of hormones you get from EVRA should not be affected by being sick (vomiting) or diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You do not need to use extra contraception if you have an upset stomach.</p><p>&nbsp;</p><p>You may have spotting or light bleeding or breast tenderness or may feel sick during the first 3&nbsp;cycles. The problem will usually go away but if it doesn&rsquo;t, check with your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date, which is stated on the label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in the original container to protect from light and moisture.</p><p>Do not store above 30 &ordm;C.</p><p>&nbsp;</p><p>Do not refrigerate or freeze.</p><p>&nbsp;</p><p>Used patches still contain some active hormones. To protect the environment, the patches should be disposed of with care. To discard the used patch, you should:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peel back the disposal label on the outside of the sachet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the used patch within the open disposal label so that the sticky surface covers the shaded area.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the label sealing the used patch within and discard, keeping out of reach of children.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What EVRA contains</strong></p><p>The active substances are norelgestromin and ethinyl estradiol. Each 20 cm2 transdermal patch contains 6 mg norelgestromin and 600 micrograms ethinyl estradiol. The active substances are released over 7 days with an average of 203 micrograms norelgestromin and 34 micrograms ethinyl estradiol being released each 24 hours.</p><p>The other ingredients are: backing layer: low-density pigmented polyethylene outer layer, polyester inner layer; middle layer: polyisobutylene/polybutene adhesive, crospovidone, non-woven polyester fabric, lauryl lactate; third layer: polyethylene terephthalate (PET) film, polydimethylsiloxane coating.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                EVRA is a thin, beige, plastic transdermal patch stamped “EVRA”. The sticky adhesive side is stuck
to the skin after removal of the clear, plastic, protective covering.
EVRA is available in the following pack sizes: Cartons containing 3, 9 or 18 patches in individual
foil-lined sachets, wrapped per three in a transparent perforated plastic film.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Manufacturer</strong>:&nbsp;LTs Lohmann Therapie- system AG, Lohmann str 2, D56626 Andernach, Germany</p><p>To contact us, go to&nbsp;&nbsp;http://www.janssen.com/contact-us</p><p>&nbsp;</p><p>SAUDI ARABIA:</p><p>&bull; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp; Fax: +966-11-205-7662</p><p>- SFDA Call Center: 19999</p><p>- E-mail:&nbsp;ritonavir, nevirapine, efavirenz)</p><p>- Website:&nbsp;https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                13/09/2021

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي دواء إيفرا على نوعين من الهرمونات الجنسية، إحداها بروجستيروني المفعول يُسمى نوريلجيسترامين والآخر إيستروجيني المفعول ويٌسمى إيثنيل أستراديول.</p><p>&nbsp;</p><p dir="RTL">ويُسمى إيفرا &quot;وسيلة منع حمل هرمونية مركبة&quot; بما أنه يحتوي على هرمونين.</p><p>&nbsp;</p><p dir="RTL">ويُستخدم لمنع الحمل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">يمنع إستخدام إيفرا المتزامن مع المنتجات الطبية التي تحتوي على أومبيتاسفير / باريتابريفير / ريتونافير ، وداسابوفير ، جليكابريفير<br />/ بيبرنتاسفير ، سوفوسبوفير / فيلباتاسفير / فوكسيلابريفير</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ملاحظات عامة</strong></p><p dir="RTL">قبل البدء في استخدام إيفرا ينبغي عليكِ قراءة المعلومات حول الجلطات الدموية الواردة بالقسم 2. من الأهمية بمكان قراءة أعراض الجلطة الدموية - انظري القسم 2 &quot;الجلطات الدموية&quot;.</p><p>&nbsp;</p><p dir="RTL"><strong>متى يتعين عليكِ عدم استخدام إيفرا</strong></p><p dir="RTL">يتعين عليكِ عدم استخدام إيفرا إذا كنتِ تعانين من أي من الحالات المُدرجة أدناه. إذا كنتِ تعانين من أي من الحالات المُدرجة أدناه، فيجب عليكِ إخبار طبيبكِ. سيتناقش معكِ الطبيب بشأن الطريقة الأخرى الأكثر ملاءمة لتنظيم النسل.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين (أو سبق لكِ أن عانيت) من جلطة دموية في وعاء دموي في الساق (خثار (DVT)) أو الرئة (انصمام رئوي (PE)) أو أعضاء أخرى في الجسم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعلمين أنك تعانين من اضطراب يؤثر على تجلط الدم لديكِ - كنقص بروتين C أو نقص بروتين S أو نقص مضاد الثرومبين الثالث أو العامل الخامس لايدن أو أضداد مضاد الشحمي الفسفوري.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ في حاجة إلى إجراء عملية أو جراحة في القدمين تستغرق مدة طويلة (انظري القسم 2 &quot;الجلطات الدموية&quot;).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق لكِ أن عانيت من مرض قلبي أو تعرضت لسكتة دماغية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين (أو سبق لكِ أن عانيت) من ذبحة صدرية (حالة تسبِّب ألمًا حادًا في الصدر وقد تكون مؤشرًا لحدوث ذبحة قلبية) أو نوبة إقفارية عابرة (أعراض السكتة الدماغية المؤقتة (TIA)).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من مرض قد يزيد من مخاطر الإصابة بجلطة في الشرايين:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري الحاد في مرحلة تؤثر على الأوعية الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المرتفع جدًا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة الدهون في الدم عند مستوى مرتفع جدًا (الكوليسترول أو الدهون الثلاثية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تُعرف باسم فرط الهوموسستئين في الدم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين (أو سبق لكِ أن عانيت) من أحد أنواع الصداع النصفي والمُسمى &quot; الشقيقة ومقدماتها &quot;.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من حساسية تجاه نوريلجيسترامين أو إيثينيل أسترادیول أو أي من المكونات الأخرى في هذا الدواء (مدرجة في القسم&nbsp;6).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن قيل لكِ بأنكِ تعانين من سرطان الثدي أو سرطان الرحم أو عنق الرحم أو المهبل.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ قد عانيتِ من أورام الكبد أو مرض كبدي بسبب أن الكبد لديكِ لا يؤدي وظيفته بالشكل الصحيح.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من نزيف مهبلي مجهول السبب.</p><p>●&nbsp; &nbsp; &nbsp; &nbsp;إذا كنتِ مصابة بمرض التهاب الكبد&nbsp; C وتتناولين منتجات دوائية تحتوي على أومبيتاسفير/باريتابريف ير/ريتونافير/داسابوفير&nbsp;(انظري أيضًا في القسم &quot;الأدوية الأخرى وإيفرا&quot;)&nbsp;.</p><p dir="RTL">لا تستخدمي هذا الدواء إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليكِ. إذا لم تكوني متأكدة من ذلك، فاستشيري طبيبكِ أو الصيدلي أو الممرضة قبل استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>متى تلزم الرعاية الخاصة مع استخدام إيفرا</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">متى يتعين عليكِ استشارة طبيبكِ؟</p><p dir="LTR"><u>&nbsp;</u></p><p dir="RTL"><u>طلب العناية الطبية العاجلة</u></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظتِ علامات محتملة لجلطة دموية مما يعني أنكِ تعانين من تجلط دم في الساق (أي خثار) أو جلطة دموية في الرئة (أي انصمام رئوي) أو ذبحة قلبية أو سكتة دماغية (انظري القسم &quot;الجلطة الدموية&quot; [الخثار] أدناه).</p><p dir="LTR">&nbsp;</p><p dir="RTL">للحصول على وصف لأعراض هذه الآثار الجانبية الخطيرة يُرجى الانتقال إلى &quot;كيفية التعرف على الجلطة الدموية&quot;.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحذيرا ت<br />بالم نتجات الطبية التي )HCV( خلال التجارب السريرية مع المرضى الذين عولجوا من عدوى فيروس التهاب الكبد الوبائي سي<br />أعلى )ALT( تحتوي على أومبيتاسفير / باريتابريفير / ريتونافير وداسابوفير مع أو بدون ريبافيرين ، حدثت ارتفاعات ترانس أميناز<br />بشكل ملحوظ أكثر شيوعًا عند النساء اللائي يستخدمن الأدوية المحتوية على إيثين يل )ULN( من 5 أضعاف الحد الأعلى الطبيعي<br />استراديول مثل<br />التي HCV مع المنتجات الطبية المضادة للفيروسات ALT وقد لوحظت أيضًا ارتفاعات .)CHCs( موانع الحمل الهرمونية المرك بة<br />تحتوي على جليكابريفير / بيبرنتاسفير وسوفوسبوفير / فيلباتاسفير / فوكسيلابريفير.<br />قبل استخدام هذا الدواء، ستحتاجين إلى مراجعة طبي بكِ لإجراء الفحص الطبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل استخدام هذا الدواء، ستحتاجين إلى مراجعة طبيبكِ لإجراء الفحص الطبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أبلغي طبيبكِ إذا كان أيٌّ من الحالات التالية ينطبق على حالتكِ.</strong></p><p>&nbsp;</p><p dir="RTL">إذا تطورت أو تفاقمت لديكِ الحالة أثناء استخدامك إيفرا، فيجب عليكِ استشارة طبيبكِ.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من داء كرون أو التهاب القولون التقرحي (مرض التهاب الأمعاء المزمن).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من داء الذئبة الحمامية الجهازية (مرض يؤثر على الجهاز المناعي الطبيعي لديكِ).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من متلازمة انحلال الدم اليوريمي (HUS - وهو اضطراب في تجلط الدم يسبِّب الفشل الكلوي).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من فقر الدم المنجلي (وهو مرض وراثي في خلايا الدم الحمراء).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من مستويات مرتفعة من الدهون في الدم (فرط غليسريد الدم الثلاثي) أو تاريخ أسري إيجابي لهذه الحالة. ارتبط فرط ثلاثي غليسريد الدم بزيادة خطر الإصابة بالتهاب البنكرياس (التهاب في البنكرياس).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ في حاجة إلى إجراء عملية أو جراحة في الرجلين تستغرق مدة طويلة (انظري القسم 2 &quot;الجلطات الدموية&quot;).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ أنجبتِ مولودًا للتو فأنتِ في مرحلة خطر الإصابة بالجلطات الدموية. يتعين عليكِ استشارة الطبيب بشأن أقرب وقت ممكن بعد الولادة يمكنكِ فيه البدء في استخدام إيفرا.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من التهاب في الأوردة تحت الجلد (التهاب الوريد الخثاري السطحي).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من توسع الأوردة.</p><p>&nbsp;</p><p dir="RTL"><strong>الجلطات الدموية</strong></p><p>&nbsp;</p><p dir="RTL">إن استخدام موانع الحمل الهرمونية المشتركة مثل إيفرا يزيد من خطر تطور حالة الجلطة الدموية مقارنة بعدم استخدام واحدة منها. في حالات نادرة يمكن أن تتسبَّب الجلطة الدموية في سد الأوعية الدموية وتسبِّب مشاكل خطيرة.</p><p>&nbsp;</p><p dir="RTL">قد تتطور الجلطات الدموية</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الأوردة (المُشار إليها باسم &quot;الخثار الوريدي&quot; أو &quot;الانصمام الخثاري الوريدي&quot; أو (VTE)).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الشرايين (المُشار إليها باسم &quot;الخثار الشرياني&quot; أو &quot;الانصمام الخثاري الشرياني&quot; أو (ATE)).</p><p>&nbsp;</p><p dir="RTL">لا يكتمل التعافي من الجلطات الدموية دائمًا. نادرًا ما قد تحدث آثار دائمة خطيرة، أو نادرًا جداً ما تكون مميتة.</p><p>&nbsp;</p><p dir="RTL"><strong>من الجدير بالذكر أن المخاطر العامة للجلطة الدموية الضارة بسبب استخدام إيفرا تكون ضئيلة.</strong></p><p>&nbsp;</p><p dir="RTL"><strong>كيفية التعرف على الجلطة الدموية</strong></p><p>&nbsp;</p><p dir="RTL">اطلبي العناية الطبية العاجلة إذا لاحظتِ أيًا من العلامات أو الأعراض التالية.</p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">هل تعانين من أي من هذه العلامات؟</p></td><td style="vertical-align:top"><p dir="RTL">ما الذي من المحتمل أنك تعانين منه؟</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في إحدى الساقين أو بطول الوريد بالساق أو القدم خاصة عندما يكون مصحوبًا بما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضعف في الساق يمكن الشعور به فقط عند الوقوف أو المشي؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الدفء في الساق المصابة؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في لون الجلد بالساق مثل الشحوب أو التحول للون الأحمر أو الأزرق.</p></td><td style="vertical-align:top"><p dir="RTL">تخثر في الوريد العميق</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع النفس المفاجئ مجهول السبب أو سرعة التنفس.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال المفاجئ مجهول السبب، والذي قد يؤدي إلى ارتفاع ضغط الدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم حاد في الصدر قد يزيد مع التنفس العميق.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوَار حاد أو دوخة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب أو عدم انتظامها.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم حاد في المعدة.</p><p dir="LTR">&nbsp;</p><p dir="RTL">إذا لم تكوني متأكدة، فتحدثي إلى الطبيب حيث أن بعض هذه الأعراض مثل السعال أو ضيق النفس قد لا يمكن تمييزها في حالة أكثر اعتدلاً مثل التهاب الجهاز التنفسي (كنزلات البرد).</p></td><td style="vertical-align:top"><p dir="RTL">انصمام رئوي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تحدث الأعراض الأكثر شيوعًا في إحدى العينين:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان فوري للبصر.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح في الرؤية غير مؤلم قد يتفاقم إلى فقدان للبصر.</p></td><td style="vertical-align:top"><p dir="RTL">تخثر الوريد الشبكي (الجلطة الدموية في العين)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر وضيق وضغط وثقل.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضغطة أو اتخام في الصدر أو الذراع أو أسفل عظم الصدر.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الامتلاء أو عسر الهضم أو الشعور بالاختناق.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في الجزء العلوي من الجسم ينتشر في الظهر والفك والحلق والذراع والمعدة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق أو الغثيان أو القيء أو الدوخة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف الشديد أو التوتر أو ضيق النفس.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة نبضات القلب أو عدم انتظامها.</p></td><td style="vertical-align:top"><p dir="RTL">ذبحة قلبية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف مفاجئ أو تنميل في الوجه أو الذراع أو الساق، خاصة على إحدى جانبي الجسم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك المفاجئ أو صعوبة في التحدث أو الفهم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة مفاجئة في الرؤية بإحدى العينين أو بكلتيهما.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة مفاجئة في المشي أو الدوخة أو فقدان التوازن أو التناسق.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع مفاجئ أو حاد أو لفترة طويلة دون سبب معروف.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي أو الإغماء المصحوب بنوبة أو غير المصحوب بها.</p><p dir="LTR">&nbsp;</p><p dir="RTL">قد تكون أعراض السكتة الدماغية قصيرة مصحوبة بتعافٍ فوري أو كامل، غير أنه ما يزال يتعين عليكِ طلب العناية الطبية العاجلة عند تعرضك لخطر الإصابة بسكتة دماغية أخرى.</p></td><td style="vertical-align:top"><p dir="RTL">السكتة الدماغية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الأطراف وتغير اللون إلى الزرقة الخفيفة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم حاد في المعدة (ألم حاد في البطن).</p></td><td style="vertical-align:top"><p dir="RTL">الجلطات الدموية التي تسد الأوعية الدموية الأخرى</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>الجلطات الدموية في الوريد</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>ماذا يمكن أن يحدث إذا تكونت الجلطة الدموية في الوريد؟</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم ربط استخدام موانع الحمل الهرمونية المركبة بزيادة مخاطر الجلطات الدموية في الوريد (الخثار الوريدي). ومع ذلك، فإن هذه الآثار الجانبية نادرة. في معظم الأحيان، تظهر في العام الأول من استخدام وسيلة منع الحمل الهرمونية المركبة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تكوَّنت الجلطة الدموية في الوريد بالساق أو القدم فمن الممكن أن تسبِّب خثارًا (DVT).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انتقلت الجلطة الدموية من الساق إلى الرئة فقد تسبِّب انصمامًا رئويًا.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من النادر جدًا أن تتكون جلطة في الوريد بعضو آخر كالعين (تخثر الوريد الشبكي).</p><p>&nbsp;</p><p dir="RTL"><strong>متى تكون مخاطر الجلطة الدموية المتفاقمة في الوريد في أعلى مستوياتها؟</strong></p><p dir="RTL">تكون مخاطر الجلطة الدموية المتفاقمة في الوريد في أعلى مستوياتها خلال العام الأول من استخدام وسيلة منع الحمل الهرمونية المركبة للمرة الأولى. قد تكون المخاطر أعلى إذا بدأتِ من جديد في استخدام وسيلة منع الحمل المركبة (نفس المنتج أو منتج مختلف) بعد فترة فاصلة 4 أسابيع فأكثر.</p><p>&nbsp;</p><p dir="RTL">بعد العام الأول، تصبح المخاطر أقل ولكن دائمًا ما تكون أعلى قليلاً إذا لم تكوني تستخدمين وسيلة منع حمل هرمونية مركبة.</p><p>&nbsp;</p><p dir="RTL">عندما تتوقفين عن استخدام إيفرا، تعود مخاطر الجلطة الدموية لديكِ إلى معدلها الطبيعي في غضون أسابيع قليلة.</p><p>&nbsp;</p><p dir="RTL"><strong>ما مخاطر الجلطة الدموية المتفاقمة؟</strong></p><p dir="RTL">تعتمد المخاطر على المخاطر الطبيعية للانصمام الخثاري الوريدي (VTE) لديكِ ونوع وسيلة منع الحمل التي تستخدمينها.</p><p>&nbsp;</p><p dir="RTL">المخاطر العامة للإصابة بالجلطة الدموية في الساق أو الرئة (الخثار أو الانصمام الرئوي) مع استخدام إيفرا تكون ضئيلة.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من بين 10000&nbsp;امرأة ممن لا يستخدمن أي وسيلة من موانع الحمل ومن غير الحوامل، تتفاقم لدى حالتين تقريبًا الإصابة بالجلطة الدموية في العام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من بين 10000&nbsp;امرأة ممن يستخدمن وسيلة من موانع الحمل التي تحتوي على ليفونورغيستريل أو نوريثيستيرون أو نورجيستيمات، تتفاقم الإصابة بالجلطة الدموية لدى 5-7&nbsp;حالات في العام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من بين 10000&nbsp;امرأة ممن يستخدمن وسيلة من موانع الحمل الهرمونية المركبة التي تحتوي على إيتونجيستريل أو نوريلجيسترامين مثل إيفرا، تتفاقم الإصابة بالجلطة الدموية لدى 6 و12&nbsp;من السيدات في العام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتفاوت مخاطر الإصابة بجلطة دموية وفقًا للتاريخ الطبي الشخصي لديكِ (انظري &quot;العوامل التي تزيد من مخاطر تعرضك لجلطة دموية&quot; أدناه).</p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">مخاطر تفاقم الجلطة الدموية في العام</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">النساء اللائي <strong>لا يستخدمن</strong> حبوبًا هرمونية مركبة</p><p dir="RTL">ولسنَ حوامل</p></td><td style="vertical-align:top"><p dir="RTL">حوالي 2&nbsp;من أصل 10000&nbsp;امرأة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">عند استخدام حبوب منع حمل هرمونية مركبة تحتوي على <strong>ليفونورغيستريل أو نوريثيستيرون أو نورجيستيمات</strong></p></td><td style="vertical-align:top"><p dir="RTL">حوالي 5-7&nbsp;من أصل 10000&nbsp;امرأة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">النساء اللاتي يستخدمن إيفرا</p></td><td style="vertical-align:top"><p dir="RTL">حوالي 6-12 من أصل 10000&nbsp;امرأة</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>العوامل التي تزيد من مخاطر تعرضك لجلطة دموية في الوريد</strong></p><p dir="RTL">إن مخاطر الجلطة الدموية مع استخدام إيفرا ضئيلة إلا أن بعض الحالات ستزيد من المخاطر. تكون المخاطر أعلى في الحالات التالية:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ بدينة جدًا (مؤشر كتلة الجسم أو (BMI) أكبر من 30&nbsp;كجم/م<sup>2</sup>).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان أحد أفراد أسرتكِ المقربين قد أُصيب بجلطة دموية في الساق أو الرئة أو في عضو آخر في سن مبكر (على سبيل المثال دون سن 50). في هذه الحالة قد تصابين باضطراب تخثر الدم الوراثي؛</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ في حاجة إلى إجراء عملية أو جراحة في الرجلين تستغرق مدة طويلة بسبب إصابة أو مرض أو إذا تم وضع قدمك في جبيرة للعظام. قد يلزم التوقف عن استخدام إيفرا لعدة أسابيع قبل إجراء الجراحة أو إذا كانت حركتك قليلة. إذا كنتِ في حاجة إلى التوقف عن استخدام إيفرا، فاستشيري طبيبكِ متى يمكنكِ البدء في استخدامه ثانية؛</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلما تقدمتِ في العمر (خاصة فيما فوق سن 35).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أنجبتِ منذ أقل من بضعة أسابيع.</p><p>&nbsp;</p><p dir="RTL">تزيد مخاطر تفاقم الجلطة الدموية كلما زادت الحالات المسببة لذلك.</p><p>&nbsp;</p><p dir="RTL">قد يزيد السفر الجوي (لمدة أكثر من 4&nbsp;ساعات) من مخاطر الجلطة الدموية مؤقتًا، وخاصة إذا كانت لديكِ بعض العوامل الأخرى المدرجة.</p><p>&nbsp;</p><p dir="RTL">من المهم إخبار طبيبكِ إذا كانت أي من هذه الحالات تنطبق عليكِ حتى لو لم تكوني متأكدة. قد يقرر طبيبكِ الحاجة إلى وقف استخدام إيفرا.</p><p>&nbsp;</p><p dir="RTL">إذا تغيرت أي حالة من الحالات المذكورة أعلاه أثناء استخدام إيفرا، كأن يعاني أحد أفراد الأسرة المقربين من خثارٍ لسبب غير معروف أو تكتسبين مزيدًا من الوزن، فأخبري طبيبكِ.</p><p>&nbsp;</p><p dir="RTL"><strong>الجلطات الدموية في الشريان</strong></p><p>&nbsp;</p><p dir="RTL"><strong>ماذا يمكن أن يحدث إذا تكونت الجلطة الدموية في الشريان؟</strong></p><p dir="RTL">مثل الجلطة الدموية في الوريد، يمكن أن تسبِّب الجلطة في الوريد مشاكل خطيرة. فعلى سبيل المثال، يمكن أن تسبِّب ذبحة قلبية أو سكتة دماغية.</p><p>&nbsp;</p><p dir="RTL"><strong>العوامل التي تزيد من مخاطر تعرضك لجلطة دموية في الشريان</strong></p><p dir="RTL">من الجدير بالذكر أن مخاطر الإصابة بذبحة قلبية أو سكتة دماغية نتيجة استخدام إيفرا تكون ضئيلة جدًا ولكنها قد تزيد في الحالات التالية:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع تقدم العمر (ما بعد سن 35).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتِ مدخنة</strong>. عند استخدام وسيلة منع حمل هرمونية مركبة مثل إيفرا، يُنصح بالتوقف عن التدخين. إذا كنتِ غير قادرة على التوقف عن التدخين ويزيد عمرك عن 35، فقد يشير عليكِ الطبيب باستخدام نوع مختلف من موانع الحمل؛</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ بدينة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من ارتفاع ضغط الدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان أحد أفراد الأسرة المقربين قد أُصيب بذبحة قلبية أو سكتة دماغية في سن مبكر (أقل من سن 50). في هذه الحالة، قد تتعرضين لمخاطر أكبر للإصابة بذبحة قلبية أو سكتة دماغية؛</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديكِ، أو لدى أحد من أفراد أسرتك المقربين، نسبة مرتفعة من الدهون في الدم (الكوليسترول أو الدهون الثلاثية).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبتِ بحالات الصداع النصفي، خاصة الصداع النصفي المترافق مع أوْرة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من مشكلة صحية في القلب (اضطراب الصمام، وهو اضطراب في انتظام ضربات القلب يُسمى الرجفان الأذيني).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من داء السكري.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ تعانين من واحدة أو أكثر من هذه الحالات أو إذا كانت أي منها حادة فقد تزيد مخاطر تفاقم الجلطة الدموية أكثر.</p><p>&nbsp;</p><p dir="RTL">إذا تغيرت أي حالة من الحالات المذكورة أعلاه أثناء استخدام إيفرا، كأن تبدئين في التدخين أو يعاني أحد أفراد الأسرة المقربين من خثارٍ لسبب غير معروف أو تكتسبين مزيدًا من الوزن، فأخبري طبيبكِ.</p><p><br />الاضطرابات&nbsp;النفسية</p><p>أبلغ بعض النساء اللائي يستخدمن وسائل منع الحمل الهرمونية بما في ذلك إيفرا عن تعرضهن للاكتئاب أو الحالة المزاجية المكتئبة.<br />قد يكون الاكتئاب خطيرًا وقد يؤدي أحيانًا إلى التفكير في الانتحار. إذا تعرضتِ لتقلبات مزاجية وأعراض الاكتئاب، فاتصلي بطبيبك<br />للحصول على المزيد من الاستشارات الطبية بأسرع ما يمكن.</p><p dir="RTL">إضافة إلى ذلك، تحدثي إلى طبيبكِ أو الصيدلي أو الممرضة قبل استخدام إيفرا إذا كنتِ قد عانيتِ أو تعانين من إحدى الحالات التالية أو أنها تفاقمت أثناء استخدام إيفرا:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعتقدين أنك قد تكونين حاملاً.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من حالات صداع ساءت أو أصبحت تحدث أكثر.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وزنك 90&nbsp;كجم (الذي يعادل 14&nbsp;حجرًا وزن كل حجر رطلان) أو أكثر.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من ضغط دم مرتفع أو أصبح ضغط الدم لديكِ أعلى.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من مرض المرارة بما في ذلك الحصوات في المرارة أو التهاب المرارة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من اضطراب دموي يُسمى البرفيرية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديكِ اضطراب في الجهاز العصبي مصحوبًا بحركات مفاجئة للجسم تُسمى &quot;مرض الرقاص &quot;.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من طفح جلدي مصحوبًا ببليستر أثناء الحمل (تُسمى &quot;هربز &nbsp;الحمل&quot;).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من فقدان السمع.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من داء السكري.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من الاكتئاب.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من الصرع أو أي مشكلة أخرى يمكن أن تسبب نوبات ( تشنجات ).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من مشكلات الكبد وتتضمن اصفرار الجلد وبياض العينين (اليرقان).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين أو سبق لكِ أن عانيتِ من &quot;بقع الحمل&quot;. تظهر هذه البقع بنية اللون التي تميل إلى الاصفرار خاصة على وجهكِ (تُسمى &quot;كلف&quot;). قد تزول هذه البقع تمامًا حتى بعد أن تتوقفي عن استخدام إيفرا. احمي جلدك من أشعة الشمس أو الأشعة فوق البنفسجية. قد يساعدك هذا على الوقاية من الإصابة بهذه البقع أو يساعدك على الوقاية من أن تزداد سوءًا.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من مشكلات في الكلى.</p><p>&nbsp;</p><p dir="RTL">إذا لم تكوني متأكدة من أن أيًّا مما ذُكِرَ أعلاه ينطبق على حالتكِ، فاستشيري طبيبك أو الصيدلي قبل استخدام إيفرا.</p><p>&nbsp;</p><p dir="RTL"><strong>الأمراض المنقولة جنسيًا</strong></p><p dir="RTL">لن يقيكِ هذا الدواء من عدوى فيروس نقص المناعة البشرية (الإيدز) أو أي أمراض منقولة جنسيًا أخرى. قد تشمل هذه الأمراض الكلاميديا والهربس التناسلي والبثور التناسلية والسيلان والتهاب الكبد ب والزهري. استخدمي دومًا الواقيات الذكرية لحماية نفسكِ من هذه الأمراض.</p><p>&nbsp;</p><p dir="RTL"><strong>الاختبارات الطبية</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ في حاجة لإجراء اختبار دم أو بول، فأخبري طبيبكِ أو موظف المعمل أنكِ تستخدمين إيفرا، حيث يمكن لموانع الحمل الهرمونية أن تؤثر على نتائج مثل هذه الاختبارات.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقات</strong></p><p dir="RTL">أُجريت الدراسات على إيفرا في الأطفال والمراهقات دون سن 18. يجب ألا يُستخدم إيفرا في الأطفال والمراهقات ممن لم يبلغن حيضتهن الأولى.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وإيفرا</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p>لا تستخدمي إيفرا إذا كنتِ مصابة بمرض التهاب الكبد&nbsp;وتتناولين منتجات دوائية تحتوي على C</p><p>أومبيتاسفير/باريتابريفير/ريتونافير/داسابوفير حيث قد تتسبب هذه الأدو ية في زيادة نتائج اختبار الدم لوظائف الكبد )زيادة في إنزيم&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; سيصف لكِ الطبيب نوعًا آخر من وسائل منع الحمل قبل بدء العلاج باستخدام هذه المنتجات الدوائية. يمكن إعادة بدء .)ALT الكبد&nbsp;</p><p>استخدام إيفرا بعد مرور أسبوعين تقريبًا من استكمال هذا العلاج. انظري القسم &quot;متى يتعين عليكِ عدم استخدام إيفرا&quot; .</p><p>&nbsp;</p><p>&nbsp;قد توقف بعض الأدوية والعلاجات العشبية إيفرا عن العمل على نحوٍ صحيح. إذا حدث ذلك فقد يحدث الحمل. إذا حدث ذلك فربما تصبحين حاملاً أو قد تتعرضين</p><p dir="RTL">لنزيف غير متوقع.</p><p>&nbsp;</p><p dir="RTL">ويتضمن ذلك الأدوية المستخدمة لعلاج:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المضادة للفيروسات الارتجاعية التي تستخدم لعلاج عدوى فيروس نقص المناعة البشرية/الإيدز وفيروس التهاب الكبد الوبائي C (ما يطلق عليها مثبطات إنزيم البروتياز ومثبطات إنزيم المنتسخة العكسية غير النيوكليوزيدية (مثل ريتونافير، نيفيرابين، إيفافيرينز).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج العدوى (مثل ريفامبيسين وجريزوفولفين ).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للنوبات (مثل باربيتورات، وتوبيراميت، وفينيتوين، وكاربامازيبين، وبريميدون، وأوكسيكاربازيبين، وفيلباميت).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوسينتان (عقار يُستخدم لعلاج ارتفاع ضغط الدم في الأوعية الدموية بالرئتين).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعشاب سانت جون (دواء عشبي لعلاج الاكتئاب).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبري طبيبكِ إذا كنتِ تتناولين:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المضادة للفيروسات القهقرية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية / الإيدز (مثل نيلفينافير وريتونافير ونيفيرابين وإيفافيرينز).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج العدوى (مثل ريفامبيسين وريفابوتين وجريزيوفولفين والبنسللين وتتراسيكلين).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للنوبات (مثل التوباماكس وفينوباربيتال وفينيتوين وكاربامازيبين وبريميدون وأوكسكاربزبين وفيلباميت وأسيتات أسليكاربازابين وروفينامايد).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (فوس) أبريبيتانت (عقار لعلاج الغثيان).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوسينتان (عقار يُستخدم لعلاج ارتفاع ضغط الدم في الأوعية الدموية بالرئتين).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعشاب سانت جون (دواء عشبي لعلاج الاكتئاب). ينبغي عدم استخدام أعشاب سانت جون أثناء استخدام إيفرا.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ تتناولين أيًا من هذه الأدوية، فقد تحتاجين إلى استخدام طريقة أخرى لتنظيم النسل (مثل الواقي الذكري أو العازل الأنثوي أو الرغوة). قد يستمر التأثير المتداخل لبعض هذه الأدوية لفترة تصل إلى 28&nbsp;يومًا بعد التوقف عن تناولها. تحدثي مع طبيبكِ أو الصيدلي حول استخدام طريقة أخرى لتنظيم النسل إذا كنتِ تستخدمين إيفرا بالتزامن مع أي من الأدوية المذكورة أعلاه.</p><p>&nbsp;</p><p dir="RTL">قد يقلل إيفرا من فعالية بعض الأدوية الأخرى مثل:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تحتوي على سيكلوسبورين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ولاموتريجين المُستخدم في علاج الصرع [قد يزيد هذا من مخاطر التعرض للنوبات (النوبات)].</p><p>&nbsp;</p><p dir="RTL">قد يحتاج طبيبكِ إلى تعديل جرعة الأدوية الأخرى: اسأل طبيبك أو الصيدلي للحصول على استشارة قبل تناول أي دواء.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدمي هذا الدواء إذا كنتِ حاملًا أو تظنين أنكِ حامل.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقفي فورًا عن استخدام هذا الدواء إذا أصبحتِ حاملاً.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدمي هذا الدواء إذا كنتِ ترضعين طبيعيًا أو تخططين لذلك.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ حاملاً أو تعتقدين أنك قد تكونين حاملاً أو كنت تخططين لإنجاب طفل، فاستشيري طبيبكِ أو الصيدلي قبل استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكنكِ القيادة واستخدام الآلات أثناء استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>مخاطر استخدام موانع الحمل الهرمونية</strong></p><p dir="RTL">تستند المعلومات التالية إلى المعلومات المتوفرة حول الحبوب المركبة لتنظيم النسل. بما أن اللاصقة الدوائية عبر الجلد إيفرا تحتوي على هرمونات مشابهة لتلك المستخدمة في الحبوب المركبة لتنظيم النسل، فمن المحتمل أن يكون لها نفس المخاطر. تحتوي جميع الحبوب المركبة لتنظيم النسل على المخاطر التي قد تؤدي إلى العجز أو الوفاة.</p><p>&nbsp;</p><p dir="RTL">ومن غير الثابت أن اللاصقة الدوائية عبر الجلد مثل إيفرا أكثر أمانًا من الحبوب المركبة لتنظيم النسل التي يتم تناولها عن طريق الفم.</p><p>&nbsp;</p><p dir="RTL"><strong>موانع الحمل الهرمونية المركبة والسرطان</strong></p><p>&nbsp;</p><p dir="RTL"><strong>سرطان عنق الرحم</strong></p><p dir="RTL">تم اكتشاف أن سرطان عنق الرحم أكثر تكرارًا في النساء اللاتي يستخدمن موانع الحمل الهرمونية المركبة.&nbsp; ومع ذلك، فقد يرجع ذلك لأسباب أخرى بما في ذلك الأمراض المنقولة جنسيًا.</p><p>&nbsp;</p><p dir="RTL"><strong>سرطان الثدي</strong></p><p dir="RTL">تم اكتشاف سرطان الثدي أكثر تكرارًا في النساء اللاتي يستخدمن موانع الحمل الهرمونية المركبة. ومع ذلك، فمن المحتمل ألا تكون وسيلة منع الحمل الهرمونية المركبة هي السبب في أن معظم السيدات يعانين من سرطان الثدي. قد يكون ذلك بسبب أنه يتم فحص النساء اللاتي يتناولن وسيلة منع الحمل المركبة بصورة أكثر تكرارًا. قد يعني ذلك أن هناك فرصة أفضل لاكتشاف سرطان الثدي. تنخفض المخاطر المتزايدة تدريجيًا بعد التوقف عن استخدام وسيلة منع الحمل الهرمونية المركبة. بعد 10&nbsp;سنوات، تكون المخاطر متشابهة في الأشخاص الذين لم يستخدموا وسيلة منع الحمل الهرمونية المركبة.</p><p>&nbsp;</p><p dir="RTL"><strong>سرطان الكبد</strong></p><p dir="RTL">في الحالات النادرة، تم اكتشاف الأورام الكبدية التي لا تُعد سرطانًا في النساء اللاتي يستخدمن موانع الحمل الهرمونية المركبة. حتى إنه من النادر اكتشاف الأورام الكبدية التي تُعد سرطانًا. قد يسبِّب ذلك نزيفًا في الجسم مصحوبًا بألم حاد في منطقة المعدة. <strong>وإذا حدث ذلك، فتحدثي إلى طبيبك فورًا.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ينبغي استعمال هذا الدواء دائمًا وفقًا لتعليمات الطبيب أو الصيدلي.</p><p>&nbsp;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فإذا لم تفعلي، فقد تزيد مخاطر حدوث الحمل لديكِ.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راجعي طبيبكِ أو الصيدلي إذا كنتِ غير متأكدة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظي دائمًا بموانع حمل غير هرمونية (مثل الواقيات الذكرية أو الرغوة أو الإسفنجة) كوسيلة احتياطية في حالة الخطأ في استخدام اللاصق.</p><p>&nbsp;</p><p dir="RTL"><strong>كم عدد اللاصقات التي تستخدمينها</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأسابيع&nbsp;1 و2 و3: &nbsp;&nbsp;&nbsp; ضعي لاصقًا واتركيه لمدة سبعة أيام بالضبط.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأسبوع&nbsp;4: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عليكِ <strong>بألا</strong> تضعي لاصقًا هذا الأسبوع.</p><p><u>&nbsp;</u></p><p dir="RTL"><strong>إذا لم تكوني قد استخدمتِ وسيلة منع حمل هرمونية أثناء دورتك السابقة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تبدئين استخدام هذا الدواء في اليوم الأول من دورتك الشهرية التالية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انقضى يوم أو عدة أيام على بداية دورتك الشهرية، فتحدثي إلى طبيبكِ بشأن استخدام وسيلة منع حمل غير هرمونية مؤقتًا.</p><p><u>&nbsp;</u></p><p dir="RTL"><strong>إذا تحولتِ من استخدام حبوب منع الحمل الفموية إلى استخدام إيفرا</strong></p><p dir="RTL">إذا تحولتِ من استخدام حبوب منع الحمل الفموية إلى استخدام هذا الدواء:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فانتظري حتى تأتي الدورة الشهرية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعي اللاصق الأول خلال الـ 24 ساعة الأولى من الدورة الشهرية.</p><p>&nbsp;</p><p dir="RTL">إذا تم وضع اللاصق بعد انقضاء اليوم 1 من دورتك الشهرية، فيتعين عليكِ ما يلي:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام وسيلة منع حمل غير هرمونية حتى اليوم 8 عند تغيير اللاصق.</p><p>&nbsp;</p><p dir="RTL">إذا لم تأتِ دورتك خلال 5&nbsp;أيام من تناول آخر حبة من حبوب منع الحمل، فاستشيري طبيبكِ قبل بداية استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تحولتِ </strong><strong>من استخدام حبوب منع الحمل التي تحتوي على البروجستيرون فقط أو الغرس أو المستخدمة عن طريق الحقن إلى استخدام إيفرا</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنكِ البدء في استخدام هذا الدواء في أي يوم بعد التوقف عن استخدام حبوب منع الحمل التي تحتوي على البروجستيرون فقط أو إزالة الغرس أو عندما يحين موعد الحقنة التالية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في اليوم الأول بعد التوقف عن استخدام حبوب منع الحمل التي تحتوي على البروجستيرون فقط أو إزالة الغرس أو عندما يحين موعد الحقنة التالية، ضعي لاصقًا.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدمي وسيلة منع حمل غير هرمونية حتى اليوم 8 عند تغيير اللاصق.</p><p>&nbsp;</p><p dir="RTL"><strong>بعد الإجهاض <em>قبل</em> 20&nbsp;أسبوعًا من الحمل</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدثي مع طبيبكِ.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنكِ البدء في استخدام هذا الدواء فورًا.</p><p>&nbsp;</p><p dir="RTL">إذا انقضى يوم أو عدة أيام على إجهاضك أو عند بداية استخدام هذا الدواء، فتحدثي إلى طبيبكِ بشأن استخدام وسيلة منع حمل غير هرمونية مؤقتًا.</p><p>&nbsp;</p><p dir="RTL"><strong>بعد الإجهاض <em>بعد</em> 20&nbsp;أسبوعًا من الحمل</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدثي مع طبيبكِ.</p><p>&nbsp;</p><p dir="RTL">يمكنكِ البدء في استخدام هذا الدواء في اليوم 21&nbsp;من الإجهاض أو في اليوم الأول من دورتك الشهرية التالية، أيهما أقرب.</p><p>&nbsp;</p><p dir="RTL"><strong>بعد الولادة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدثي مع طبيبكِ.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديكِ طفل ولا ترضعين، فيتعين عليكِ عدم البدء في استخدام هذا الدواء في أقل من 4&nbsp;أسابيع بعد الولادة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بدأتِ في الاستخدام فيما بعد 4&nbsp;أسابيع من الولادة، فاستخدمي وسيلة منع حمل غير هرمونية أخرى مع هذا الدواء في خلال أول 7&nbsp;أيام.</p><p>&nbsp;</p><p dir="RTL">إذا حدث الجماع بعد ولادة طفلك، فانتظري حتى تأتي أول دورة شهرية أو استشيري طبيبكِ للتأكد من أنكِ لستِ حاملاً قبل استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا كنتِ ترضعين طبيعيًا</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدثي مع طبيبكِ.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدمي هذا الدواء إذا كنتِ ترضعين طبيعيًا أو تخططين لذلك (انظري أيضًا القسم 2 الحمل والرضاعة الطبيعية).</p><p><u>&nbsp;</u></p><p dir="RTL"><strong>معلومات مهمة يجب اتباعها عند استخدام اللاصق</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عليكِ بتغيير إيفرا في نفس اليوم من كل أسبوع. حيث إنه مصمم للعمل على مدار 7&nbsp;أيام.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تدعي أكثر من 7&nbsp;أيام متتالية تمر عليكِ دون ارتداء لاصق.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتدي لاصقًا واحدًا فقط في نفس الوقت.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقصي اللاصق أو تعبثي به بأي طريقة كانت.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تضعي اللاصق على الجلد الذي يعلوه الاحمرار أو الملتهب أو المقطوع.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حتى يعمل اللاصق على نحوٍ صحيح، يجب أن يلتصق بالجلد بإحكام.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغطي على اللاصق لأسفل بإحكام حتى تلتصق الحواف جيدًا.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدمي الكريمات أو الزيوت أو الغسول أو المسحوق أو مستحضرات التجميل على الجلد في الموضع الذي تضعين فيه اللاصق أو بالقرب من اللاصق الذي ترتدينه. فقد يؤدي ذلك إلى ارتخاء اللاصق.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تضعي لاصقًا جديدًا على نفس المنطقة من الجلد التي كان عليها اللاصق القديم. فإذا فعلتِ ذلك، فمن المحتمل أن يسبِّب لكِ تهيجًا.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عليكِ بالتحقق كل يوم للتأكد من أن اللاصق لم يسقط.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حافظي على استخدام اللاصقات حتى لو لم يحدث الجماع كثيرًا.</p><p><img alt="" width="192" height="620" src="data:image/png;base64,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" /><img alt="" width="212" height="791" src="data:image/png;base64,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" /></p><p dir="RTL"><strong>كيف تستخدمين اللاصق:</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">إذا كانت هذه هي المرة الأولى التي تستخدمين فيها إيفرا، فانتظري حتى يأتي اليوم الذي تحدث فيه دورتك الشهرية.</p><p dir="LTR">&nbsp;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعي اللاصق الأول خلال الـ 24&nbsp;ساعة الأولى من الدورة الشهرية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم وضع اللاصق بعد اليوم الأول من الدورة الشهرية، فاستخدمي وسيلة منع حمل غير هرمونية حتى اليوم 8 عند تغيير اللاصق.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سيكون اليوم الذي تضعين فيه اللاصق الأول لكِ هو اليوم 1. سيكون &quot;يوم استبدال اللاصق&quot; في نفس اليوم من كل أسبوع.</strong></p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">اختاري مكانًا بجسمك تضعين عليه اللاصق.</p><p dir="LTR">&nbsp;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعي اللاصق دائمًا على جلد نظيف وجاف وخالٍ من الشعر.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعيه على الأرداف أو البطن أو أعلى الذراع الخارجي أو المنطقة العليا من الظهر - الأماكن التي لا تحتك بها الملابس الضيقة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تضعي أبداًاللاصق على الثدي</strong>.</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">افتحي الكيس الرقيق بأصابعكِ.</p><p dir="LTR">&nbsp;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افتحيه بتمزيقه بطول الحافة (لا تستخدمي المقص).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسكي طرف اللاصق بإحكام وانزعيه برفق من الكيس الرقيق.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك واقٍ شفاف يغطي اللاصق.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يمكن للاصقات أحيانًا أن تلتصق بالجزء الداخلي من الكيس - احرصي على عدم إزالة الغطاء الشفاف عن طريق الخطأ أثناء إزالة اللاصق.</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم انزعي نصف الغطاء الواقي الشفاف بعيدًا (انظري إلى الصورة). حاولي ألا تلمسي السطح اللاصق.</p><p dir="LTR"><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">ضعي اللاصق على الجلد.</p><p dir="LTR">&nbsp;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم انزعي النصف الآخر من الغطاء.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغطي بإحكام لأسفل على اللاصق براحة يدك لمدة 10&nbsp;ثوانٍ.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكدي أن الحواف ملتصقة جيدًا.</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR"><u>&nbsp;</u></p><p dir="LTR"><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">ارتدي اللاصق لمدة 7&nbsp;أيام (أسبوع واحد).</p><p dir="LTR">&nbsp;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في &quot;يوم استبدال اللاصق&quot; الأول، اليوم 8 انزعي اللاصق المستخدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعي لاصقًا جديدًا على الفور.</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في اليوم 15 (الأسبوع 3) انزعي اللاصق المستخدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعي لاصقًا جديدًا آخر.</p><p dir="LTR">&nbsp;</p><p dir="RTL">يصبح المجموع ثلاثة أسابيع باستخدام اللاصقات.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>للمساعدة على توقف التهييج، لا تضعي اللاصق الجديد على نفس المنطقة من الجلد الذي وضعتِ عليها اللاصق السابق</strong>.</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">لا ترتدي لاصقًا في الأسبوع 4 (من اليوم 22&nbsp;حتى اليوم 28).</p><p dir="LTR">&nbsp;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>من المفترض أن تحدث الدورة الشهرية خلال هذا الوقت.</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلال هذا الأسبوع تكونين في مأمنٍ من الحمل فقط إذا بدأتِ استخدام اللاصق التالي في موعده.</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">فيما يتعلق بالدورة التالية المكونة من أربعة أسابيع.</p><p dir="LTR">&nbsp;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعي لاصقًا جديدًا في &quot;يوم استبدال اللاصق&quot; الطبيعي، اليوم التالي لليوم 28.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>عليكِ بالقيام بذلك</strong> <strong>سواء عندما تبدأ الدورة الشهرية أو تنتهي</strong>.</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">إذا كنتِ تريدين تغيير &quot;يوم استبدال اللاصق&quot; ليكون في يومٍ مختلف من الأسبوع، فتحدثي إلى طبيبكِ. ستحتاجين إلى إتمام الدورة الحالية وإزالة اللاصق الثالث في اليوم الصحيح. أثناء الأسبوع 4، يمكنكِ اختيار يوم استبدال جديد ووضع اللاصق الأول في ذلك اليوم. لا تدعي أبداً أكثر من 7&nbsp;أيام متتالية تمر عليكِ دون استخدام اللاصق.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ تريدين تأخير الدورة الشهرية، فضعي اللاصق في بداية الأسبوع 4 (اليوم 22) بدلاً من عدم استخدام اللاصق في الأسبوع 4. قد تعانين من نزيف خفيف أو نزيف اختراقي. لا تستخدمي أكثر من 6&nbsp;لاصقات (فيما لا يزيد عن 6&nbsp;أسابيع) متتالية. عندما تستخدمين 6&nbsp;لاصقات متتالية (في 6&nbsp;أسابيع متتالية)، لا تضعي لاصقًا في الأسبوع 7. بعد مرور 7&nbsp;أيام من عدم استخدام اللاصق، ضعي لاصقًا جديدًا وأعيدي الدورة باعتبار أن ذلك هو اليوم رقم 1. تحدثي مع طبيبكِ قبل أن تقرري تأخير الدورة الشهرية.</p><p>&nbsp;</p><p dir="RTL"><strong>ممارسة الأنشطة اليومية أثناء استخدام اللاصقات</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تؤثر الأنشطة الطبيعية كالاستحمام باستخدام حمام بخار وممارسة الرياضة على كفاءة اللاصق.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم تصميم اللاصق ليظل في مكانه أثناء ممارسة هذه الأنواع من الأنشطة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومع ذلك، يتعين عليكِ التأكد من أن هذا اللاصق لا يسقط بعد القيام بهذه الأنشطة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا كنتِ في حاجة إلى وضع اللاصق في منطقة جديدة بجسمك في يوم غير &quot;يوم استبدال اللاصق&quot;</strong></p><p dir="RTL">إذا تسبَّب اللاصق في حدوث التهاب أو أصبحتِ لا تشعرين بالراحة أثناء استخدامه:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيمكنكِ نزعه واستبداله بلاصقٍ جديد في مكان مختلف على الجسم حتى &quot;يوم استبدال اللاصق&quot; التالي&quot;.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنكِ ارتداء لاصق واحد فقط في نفس الوقت.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا كنتِ تواجهين مشكلة في تذكر تغيير اللاصق</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدثي مع طبيبكِ أو الصيدلي أو الممرضة. فقد يكون قادرًا على<strong> </strong>استبدال اللاصق بما يكون أسهل لكِ. كما قد يتحدث إليكِ إذا كنتِ في حاجة إلى استخدام وسيلة أخرى لمنع الحمل.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أصبح اللاصق مرتخيًا أو ارتفع ناحية الحواف أو سقط</strong></p><p>&nbsp;</p><p dir="RTL"><strong>لأقل من يومٍ واحدٍ</strong> (حتى 24&nbsp;ساعة):</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحاولي وضعه مرة أخرى أو وضع لاصق آخر على الفور.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يلزم استخدام وسيلة منع حمل احتياطية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يبقى &quot;يوم استبدال اللاصق&quot; كما هو.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحاولي إرجاع اللاصق إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم يعد يلصق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصبح متماسكًا بنفسه أو بسطحِ آخر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصبح ملتصقًا بمادة أخرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرة الثانية التي يرتخي فيها أو يسقط.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدمي الأشرطة أو تلفيها لتحافظي على اللاصق في مكانه.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تتمكني من استعادة اللاصق، فضعي لاصقًا جديدًا على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>لأكثر من يومٍ واحدٍ </strong>(24&nbsp;ساعة أو أكثر)<strong> </strong>أو إذا لم تكوني متأكدة من المدة:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابدئي دورة جديدة من أربعة أسابيع على الفور بوضع لاصقٍ جديد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديكِ الآن يوم 1 جديد و&quot;يوم استبدال لاصق&quot; جديد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليكِ استخدام وسيلة منع حمل غير هرمونية على سبيل الاحتياط للأسبوع الأول من الدورة الجديدة.</p><p>&nbsp;</p><p dir="RTL">قد يحدث الحمل إذا لم تتبعي هذه التعليمات.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حالة نسيان تغيير اللاصقة</strong></p><p>&nbsp;</p><p dir="RTL"><strong>في بداية أي دورة لاصق (الأسبوع 1 (اليوم 1)):</strong></p><p dir="RTL">إذا نسيتِ وضع اللاصق، فقد تكونين عرضة لمخاطر كبيرة على وجه التحديد أو قد تصبحين حاملاً.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليكِ استخدام وسيلة منع حمل غير هرمونية على سبيل الاحتياط لأسبوعٍ واحدٍ.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعي اللاصق الأول من دورة الاستعمال الجديدة بمجرد أن تتذكري.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديكِ الآن &quot;يوم استبدال اللاصق&quot; جديد ويوم 1 جديد.</p><p>&nbsp;</p><p dir="RTL"><strong>في منتصف دورة اللاصق</strong> <strong>(الأسبوع&nbsp;2 أو 3):</strong></p><p dir="RTL">إذا نسيتِ استبدال اللاصق لمدة يومٍ أو يومين<strong> </strong>(حتى 48 ساعة):</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيجب عليكِ وضع لاصقٍ جديدٍ بمجرد أن تتذكري.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعي اللاصق التالي في &quot;يوم استبدال اللاصق&quot; الاعتيادي.</p><p>&nbsp;</p><p dir="RTL">لا يلزم استخدام وسيلة منع حمل احتياطية.</p><p>&nbsp;</p><p dir="RTL"><strong>لأكثر من يومين </strong>(48&nbsp;ساعة أو أكثر)<strong>:</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيتِ استبدال اللاصق لمدة أكثر من يومين، فقد تصبحين حاملاً.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليكِ البدء في دورة جديدة من أربعة أسابيع بمجرد تذكركِ بوضع لاصقٍ جديد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديكِ الآن &quot;يوم استبدال اللاصق&quot; مختلف ويوم 1 جديد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليكِ استخدام وسيلة منع حمل احتياطية للأسبوع الأول من الدورة الجديدة.</p><p>&nbsp;</p><p dir="RTL"><strong>في نهاية دورة اللاصق (الأسبوع&nbsp;4):</strong></p><p dir="RTL">في حالة نسيان خلع اللاصق:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزعيه بمجرد أن تتذكري.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابدئي الدورة التالية في &quot;يوم استبدال اللاصق&quot; الاعتيادي، اليوم التالي لليوم 28.</p><p>&nbsp;</p><p dir="RTL">لا يلزم استخدام وسيلة منع حمل احتياطية.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا كنتِ تعانين من نزيف متغيب أو غير منتظم مع استخدام إيفرا</strong></p><p dir="RTL">فقد يتسبَّب هذا الدواء في الإصابة بنزيفٍ مهبلي غير متوقع أو ظهور بقع &nbsp;أثناء الأسابيع التي تستخدمين فيها اللاصق.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادة ما يتوقف هذا بعد الدورات القليلة الأولى.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما قد يتسبَّب وجود أخطاء في استخدام اللاصقات في &nbsp;ظهور بقع ونزيف خفيف.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استمري في استخدام هذا الدواء وإذا استمر النزيف لما بعد الدورات الثلاث الأولى، فتحدثي إلى طبيبكِ أو الصيدلي.</p><p>&nbsp;</p><p dir="RTL">إذا لم تأتِ الدورة الشهرية أثناء استخدام إيفرا<strong> </strong>في الأسبوع الخالي من اللاصق (الأسبوع 4)، فيتعين عليكِ الاستمرار في استخدام لاصق جديد في &quot;يوم استبدال اللاصق&quot; الاعتيادي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تستخدمين هذا الدواء بصورة صحيحة وليس لديكِ دورة شهرية، فلا يعني هذا بالضرورة أنكِ حامل.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومع ذلك، إذا فقدتِ دورتين متتاليتين، فتحدثي إلى طبيبكِ أو الصيدلي فقد تكونين<strong> </strong>حاملا.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا استخدمتِ لاصق إيفرا أكثر مما ينبغي (أكثر من لاصق إيفرا واحد في نفس الوقت)</strong></p><p dir="RTL">فأقلعي عن استخدام اللاصقات وتحدثي إلى الطبيب في الحال.</p><p>&nbsp;</p><p dir="RTL">قد يتسبب استخدام العديد من اللاصقات في إصابتك بأحد الأعراض التالية:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالرغبة في القيء (الغثيان) والتقيؤ (القيء).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من المهبل.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفتِ عن استخدام إيفرا</strong></p><p dir="RTL">قد تعانين من دورة شهرية غير منتظمة أو قليلة أو قد لا تحدث. غالبًا ما يحدث هذا في أول ثلاثة شهور وخاصة إذا لم تكن الدورات الشهرية لديكِ منتظمة قبل البدء في استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديكِ أي أسئلة إضافية عن استخدام هذا الدواء، فاسألي طبيبكِ أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم إصابة الجميع بها. إذا أُصبتِ بأي من الآثار الجانبية، وخاصة إذا كانت حادة أو مستمرة أو طرأ أي تغير على صحتك تعتقدين أنه بسبب استخدام إيفرا، فينبغي استشارة طبيبكِ.</p><p>&nbsp;</p><p dir="RTL">توجد مخاطر متزايدة للإصابة بالجلطات الدموية في الأوردة (الخثار الوريدي) أو الجلطات الدموية في الشرايين (الخثار الشرياني) في جميع النساء اللاتي يستخدمن موانع الحمل الهرمونية المركبة. للحصول على معلومات تفصيلية حول المخاطر المختلفة الناتجة عن استخدام موانع الحمل الهرمونية المركبة، يُرجى الرجوع إلى القسم 2 &quot;ما تحتاجين إلى معرفته قبل استخدام إيفرا&quot;.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا (قد تؤثر على أكثر من 1 من كل 10&nbsp;نساء):</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الثدي.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر على ما يصل إلى 1 من كل 10&nbsp;نساء):</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب مهبلي فطري، يُسمى أحيانًا القلاع.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في المزاج مثل الاكتئاب أو تغير في الحالة المزاجية أو تقلبات مزاجية أو التوتر أو البكاء.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع نصفي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمعدة أو انتفاخ.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء أو إسهال.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب أو طفح جلدي أو حكة جلدية أو تهيج جلدي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الثدي مثل الألم أو التضخم أو أورام الثدي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نمط الحيض الشهري أو تشنجات الرحم أو دورات شهرية مؤلمة أو إفرازات مهبلية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشاكل الناتجة عن وضع اللاصق على الجلد مثل الاحمرار أو التهيج أو الحكة أو الطفح.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء أو التوعك بصفة عامة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر على ما يصل إلى 1 من كل 100&nbsp;امرأة):</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي، شرى.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم الناتج عن احتباس الماء في الجسم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة الدهون في الدم (مثل الكوليسترول أو الدهون الثلاثية).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النوم (الأرق).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الرغبة في الجنس.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إكزيما، احمرار الجلد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنتاج غير طبيعي في لبن الثدي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ما قبل الحيض.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف مهبلي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل أخرى ناتجة عن وضع اللاصق على الجلد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم أو زيادة في ضغط الدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشهية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الحساسية لأشعة الشمس.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر على ما يصل إلى 1 من كل 1000&nbsp;امرأة):</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دموية ضارة في الوريد أو الشريان على سبيل المثال:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الساق أو القدم (أي الخثار)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الرئة (أي الانصمام الرئوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذبحة قلبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكتة دماغية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض سكتة دماغية بسيطة أو سكتة دماغية مؤقتة تُعرف باسم نوبة إقفارية عابرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية في الكبد أو المعدة / الأمعاء أو الكلى أو العين.</p><p dir="RTL">قد تكون فرصة التعرض للجلطة الدموية أعلى إذا كانت لديكِ أي من الحالات الأخرى التي تزيد من هذه المخاطر (انظري القسم 2 للحصول على مزيدٍ من المعلومات حول الحالات التي تزيد من مخاطر الإصابة بالجلطات الدموية وأعراض الجلطة الدموية).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الثدي أو سرطان عنق الرحم أو سرطان الكبد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشاكل الناتجة عن وضع اللاصق على الجلد مثل الطفح الجلدي المصحوب بالبليستر أو القرح.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أورام غير سرطانية (حميدة) في الثدي أو الكبد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أورام ليفية رحمية في الرحم (الرحم).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغضب أو الشعور بالإحباط.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الرغبة في الجنس.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تذوق غير طبيعي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل عند ارتداء العدسات اللاصقة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حادة مفاجئة في ضغط الدم (نوبة فرط الضغط).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المرارة أو القولون.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلايا غير طبيعية في عنق الرحم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع بنية اللون أو بقع على الوجه.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصى في المرارة أو انسداد في القناة الصفراوية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد وبياض العينين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدلات نسبة السكر في الدم أو الأنسولين غير طبيعية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الفم أو الحلق أو اللسان.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي المصحوب بالعقيدات الحمراء المؤلمة على السيقان أو الساقين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة الجلدية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلد المتقشر أو الجلد المائل للتقشر أو الحكة أو احمرار الجلد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبح إفراز لبن الرضاعة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفرازات مهبلية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل في الساقين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الذراعين أو اليدين أو الساقين أو القدمين.</p><p dir="RTL"><strong>إذا كان لديكِ اضطراب في المعدة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ألا تتأثر كمية الهرمونات التي تحصلين عليها من إيفرا بالإعياء (القيء) أو الإسهال.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنت لستِ في حاجة إلى استخدام وسيلة حمل إضافية إذا كنتِ تعانين من اضطراب في المعدة.</p><p>&nbsp;</p><p dir="RTL">قد تعانين من تنقيط أو نزيف خفيف أو ألم في الثدي أو قد تشعرين بالإعياء أثناء الدورات الثلاث الأولى. غالبًا ما ستزول المشكلة ولكن إذا استمرت، فتحققي من الأمر مع طبيبكِ أو الصيدلي.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرضتِ لأي آثار جانبية، فتحدثي إلى طبيبك أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مُدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكن أن تساعدي على توفير مزيد من المعلومات حول أمان هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدمي هذا الدواء بعد تاريخ انتهاء الصلاحية المحدد على الشريط اللاصق بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">يُخزَّن في العلبة الأصلية لحمايته من الضوء والرطوبة.</p><p dir="RTL">يُمنع التخزين في درجة حرارة أعلى من 30&nbsp;درجة مئوية</p><p dir="RTL">يُمنع الحفظ في الثلاجة أو تجميده.</p><p>&nbsp;</p><p dir="RTL">لا تزال اللاصقات المستخدمة تحتوي على بعض الهرمونات النشطة. لحماية البيئة، يجب التخلص من اللاصقات بعناية. للتخلص من اللاصق المستعمل، يتعين عليكِ:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازالة الملصق المخصصة الموجودة في الجهة الخارجية من الحافظة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وضع اللاصق المستعمل داخل الوريقة بحيث تغطي الجهة القابلة للصق المنطقة المظللة من الوريقة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعادة غلق الملصق بحيث يكون اللاصق بالداخل ورميها في منطقة مناسبة وبعيدة عن متناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعودي بحاجة إلى استخدامها. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات دواء إيفرا</strong></p><p dir="RTL">المواد الفعَّالة هي نوريلجيسترامين وإيثينيل أستراديول. يحتوي كل 20&nbsp;سم<sup>2</sup> من اللاصق الدوائي عبر الجلد على 6&nbsp;مج من نوريلجيسترامين و600&nbsp;ميكروجرام من إيثينيل أستراديول. يتم إخراج المواد الفعالة على مدار 7&nbsp;أيام بمعدل 203&nbsp;ميكروجرامات من نوريلجيسترامين و34 ميكروجرامًا من إيثينيل أستراديول يتم إخراجها كل 24&nbsp;ساعة.</p><p>&nbsp;</p><p dir="RTL">المكونات الأخرى هي: طبقة الدعم: طبقة خارجية من أكسيد بولي إيثيلين الصبغي منخفض الكثافة وطبقة داخلية من البوليستر وطبقة وسطى: مادة لاصقة من البوليسوبتيلين / البوليبتين وكروسبوفيدون والقماش البوليستر غير المنسوج ولاكتات اللوريل والطبقة الثالثة: رقاقة من بولي إيثيلين تيرفثالات (PET) وطلاء ثنائي ميثيل بولي سيلوكسان.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل عبوة إيفرا ومحتوياتها</strong></p><p dir="RTL">إيفرا عبارة عن لاصق عبر الجلد بلاستيكي لونه بني فاتح رقيق مختوم بكلمة &quot;EVRA&quot;. يُلصق الجانب اللاصق بالجلد بعد إزالة الغطاء الواقي البلاستيكي الشفاف.</p><p>&nbsp;</p><p dir="RTL">يتوفر دواء إيفرا في عبوات بالأحجام التالية: تحتوي العبوات الكرتونية على 3 أو 9 أو 18 لاصقًا في حافظات مبطنة فردية كل ثلاث لاصقات منها ملفوفة في شريط بلاستيكي مثقوب شفاف.</p><p>&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنّعة</strong></p><p dir="RTL">ال تي اس لوهمان ثيرابي &ndash; سيستيم ايه جي، لوهمان اس تي ار 2 ،دي 56626 انديرناش، المانيا</p><p dir="RTL">للاتصال بنا، يُرجى الانتقال إلى الصفحة&nbsp; &nbsp;&nbsp;http://www.janssen.com/contact-us</p><p dir="RTL">للإبلاغ عن أي عرض )أعراض( جانبيةّ:<br />&bull; المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقظ الدوائ ي<br />+966-11-205- رقم الفاك س: 7662 o<br />مركز الاتصالات في هيئة الغذاء والدواء السعودية:1999&nbsp; &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر تنقيح لهذه النشرة 13 سبتمبر 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 
EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 20 cm2 transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE). 
 
Each transdermal patch releases an average of 203 micrograms of NGMN and 33.9 micrograms of EE per 24 hours. Medicinal product exposure is more appropriately characterised by the pharmacokinetic profile (see section 5.2). 
 
For the full list of excipients, see section 6.1. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Transdermal patch. 
 
Thin, matrix-type transdermal patch consisting of three layers. 
 
The outside of the backing layer is beige and heat-stamped “EVRA”. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Female contraception</p><p>&nbsp;</p><p>EVRA is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.</p><p>&nbsp;</p><p>The decision to prescribe EVRA should take into consideration the individual woman&rsquo;s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with EVRA compares with other CHCs (see sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>To achieve maximum contraceptive effectiveness, patients must be advised to use EVRA exactly as directed. For initiation instructions see &lsquo;How to start EVRA&rsquo; below.</p><p>&nbsp;</p><p>Only one transdermal patch is to be worn at a time.</p><p>&nbsp;</p><p>Each used transdermal patch is removed and immediately replaced with a new one on the same day of the week (Change Day) on Day 8 and Day 15 of the cycle. Transdermal patch changes may occur at any time on the scheduled Change Day. The fourth week is transdermal patch-free starting on Day 22.</p><p>&nbsp;</p><p>A new contraceptive cycle begins on the next day following transdermal patch-free week; the next EVRA transdermal patch should be applied even if there has been no withdrawal bleeding or if withdrawal bleeding has not yet stopped.</p><p>&nbsp;</p><p>Under no circumstances should there be more than a 7-day transdermal patch-free interval between dosing cycles. If there are more than 7 transdermal patch-free days, the user may not be protected against pregnancy. A non-hormonal contraceptive must then be used concurrently for 7 days. The risk of ovulation increases with each day beyond the recommended contraceptive-free period. If intercourse has occurred during such an extended transdermal patch-free interval, the possibility of pregnancy should be considered.</p><p><em>&nbsp;</em></p><p><em><u>Special populations</u> </em></p><p>&nbsp;</p><p><em>Body weight equal or greater than 90 kg </em></p><p>Contraceptive efficacy may be decreased in women weighing equal or greater than 90 kg.</p><p>&nbsp;</p><p><em>Renal impairment </em></p><p>EVRA has not been studied in women with renal impairment. No dose adjustment is necessary but as there is a suggestion in the literature that the unbound fraction of ethinyl estradiol is higher, EVRA should be used with supervision in this population.</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>EVRA has not been studied in women with hepatic impairment. EVRA is contraindicated in women with hepatic impairment (see section 4.3).</p><p>&nbsp;</p><p><em>Post-menopausal women </em></p><p>EVRA is not indicated for post-menopausal women and is not intended for use as hormonal replacement therapy.</p><p>&nbsp;</p><p><em>Paediatric population </em></p><p>Safety and efficacy have not been established in adolescents under 18 years of age. There is no relevant use of EVRA in children and pre-menarchal adolescents.</p><p>&nbsp;</p><p>Method of administration</p><p>EVRA should be applied to clean, dry, hairless, intact healthy skin on the buttock, abdomen, upper outer arm or upper torso, in a place where it will not be rubbed by tight clothing. EVRA should not be placed on the breasts or on skin that is red, irritated or cut. Each consecutive transdermal patch should be applied to a different place on the skin to help avoid potential irritation, although they may be kept within the same anatomic site.</p><p>&nbsp;</p><p>The transdermal patch should be pressed down firmly until the edges stick well.</p><p>&nbsp;</p><p>To prevent interference with the adhesive properties of the transdermal patch, no make-up, creams, lotions, powders or other topical products should be applied to the skin area where the transdermal patch is placed or where it will be applied shortly.</p><p>&nbsp;</p><p>It is recommended that users visually check their transdermal patch daily to ensure continued proper adhesion.</p><p>&nbsp;</p><p>The EVRA transdermal patch should not be cut, damaged or altered in any way as this may compromise contraceptive effectiveness.</p><p>&nbsp;</p><p>Used transdermal patches should be discarded carefully in accordance with the instructions given in section 6.6.<strong> </strong></p><p>&nbsp;</p><p>How to start EVRA</p><p>&nbsp;</p><p><em>When there has been no hormonal contraceptive use in the preceding cycle </em></p><p>Contraception with EVRA begins on the first day of menses. A single transdermal patch is applied and worn for one full week (7 days). The day the first transdermal patch is applied (Day 1/Start Day) determines the subsequent Change Days. The transdermal patch Change Day will be on this day every week (cycle Days 8, 15, 22 and Day 1 of the next cycle). The fourth week is transdermal patch-free starting on Day 22.</p><p>&nbsp;</p><p>If Cycle 1 therapy starts after first day of the menstrual cycle, a non-hormonal contraceptive should be used concurrently for the first 7 consecutive days of the first treatment cycle only.</p><p>&nbsp;</p><p><em>When switching from an oral combined contraceptive </em></p><p>Treatment with EVRA should begin on the first day of withdrawal bleeding. If there is no withdrawal bleeding within 5 days of the last active (hormone containing) tablet, pregnancy must be ruled out prior to the start of treatment with EVRA. If therapy starts after the first day of withdrawal bleeding, a non-hormonal contraceptive must be used concurrently for 7 days.</p><p>&nbsp;</p><p>If more than 7 days elapse after taking the last active oral contraceptive tablet, the woman may have ovulated and should, therefore, be advised to consult a physician before initiating treatment with EVRA. If intercourse has occurred during such an extended pill-free interval, the possibility of pregnancy should be considered.</p><p>&nbsp;</p><p><em>When changing from a progestogen-only-method </em></p><p>The woman may switch any day from the progestogen-only pill (from an implant on the day of its removal, from an injectable when the next injection would be due), but a back-up barrier method of birth control must be used during the first 7 days.</p><p><em>&nbsp;</em></p><p><em>Following abortion or miscarriage </em></p><p>After an abortion or miscarriage that occurs before 20 weeks gestation, EVRA may be started immediately. An additional method of contraception is not needed if EVRA is started immediately. Be advised that ovulation may occur within 10 days of an abortion or miscarriage.</p><p>&nbsp;</p><p>After an abortion or miscarriage that occurs at or after 20 weeks gestation, EVRA may be started either on Day 21 post-abortion or on the first day of the first spontaneous menstruation, whichever comes first. The incidence of ovulation on Day 21 post abortion (at 20 weeks gestation) is not known.</p><p>&nbsp;</p><p><em>Following delivery </em></p><p>Users who choose not to breast-feed should start contraceptive therapy with EVRA no sooner than 4 weeks after child-birth. When starting later, the woman should be advised to additionally use a barrier method for the first 7 days. However, if intercourse has already occurred, pregnancy should be excluded before the actual start of EVRA or the woman has to wait for her first menstrual period.</p><p>&nbsp;</p><p>For breast-feeding women, see section 4.6.</p><p>&nbsp;</p><p>What to do if the transdermal patch comes off or partly detaches</p><p>If the EVRA transdermal patch partly or completely detaches and remains detached, insufficient medicinal product delivery occurs.</p><p>&nbsp;</p><p>If EVRA remains even partly detached:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for less than one day (up to 24 hours): it should be re-applied to the same place or replaced with a new EVRA transdermal patch immediately. No additional contraceptive is needed. The next EVRA transdermal patch should be applied on the usual &ldquo;Change Day&rdquo;.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for more than one day (24 hours or more) or if the user is not aware when the transdermal patch has lifted or become detached: the user may not be protected from pregnancy: The user should stop the current contraceptive cycle and start a new cycle immediately by applying a new EVRA transdermal patch. There is now a new &ldquo;Day 1&rdquo; and a new &ldquo;Change Day&rdquo;. A non-hormonal contraceptive must be used concurrently for the first 7 days of the new cycle only.</p><p>A transdermal patch should not be re-applied if it is no longer sticky; a new transdermal patch should be applied immediately. Supplemental adhesives or bandages should not be used to hold the EVRA transdermal patch in place.</p><p>&nbsp;</p><p>If subsequent EVRA transdermal patch change days are delayed</p><p>&nbsp;</p><p><em>At the start of any transdermal patch cycle (Week One/Day 1) </em></p><p>The user may not be protected from pregnancy. The user should apply the first transdermal patch of the new cycle as soon as remembered. There is now a new transdermal patch &ldquo;Change Day&rdquo; and a new &ldquo;Day 1&rdquo;. A non-hormonal contraceptive must be used concurrently for the first 7 days of the new cycle. If intercourse has occurred during such an extended transdermal patch-free interval, the possibility of pregnancy should be considered.</p><p>&nbsp;</p><p><em>In the middle of the cycle (Week Two/Day 8 or Week Three/Day 15) </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for one or two days (up to 48 hours): The user should apply a new EVRA transdermal patch immediately. The next EVRA transdermal patch should be applied on the usual &ldquo;Change Day&rdquo;. If during the 7 days preceding the first skipped day of transdermal patch application, the transdermal patch was worn correctly, no additional contraceptive use is required.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for more than two days (48 hours or more):<em> </em>The user may not be protected from pregnancy. The user should stop the current contraceptive cycle and start a new four-week cycle immediately by putting on a new EVRA transdermal patch. There is now a new &ldquo;Day 1&rdquo; and a new &ldquo;Change Day&rdquo;. A non-hormonal contraceptive must be used concurrently for the first 7 consecutive days of the new cycle.</p><p>&nbsp;</p><p><em>At the end of the cycle (Week Four/Day 22)</em></p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the EVRA transdermal patch is not removed at the beginning of Week 4 (Day 22), it should be removed as soon as possible. The next cycle should begin on the usual &ldquo;Change Day&rdquo;, which is the day after Day 28. No additional contraceptive use is required.</p><p>&nbsp;</p><p>Change day adjustment<em> </em></p><p>In order to postpone a menstrual period for one cycle, the woman must apply another transdermal patch at the beginning of Week 4 (Day 22) thus not observing the transdermal patch-free interval. Breakthrough bleeding or spotting may occur. After 6 consecutive weeks of transdermal patch wear, there should be a transdermal patch-free interval of 7 days. Following this, the regular application of EVRA is resumed.</p><p>&nbsp;</p><p>If the user wishes to move the Change Day the current cycle should be completed, removing the third</p><p>EVRA transdermal patch on the correct day. During the transdermal patch-free week a new Change Day may be selected by applying the first EVRA transdermal patch of the next cycle on the first occurrence of the desired day. In no case should there be more than 7 consecutive transdermal patch-free days. The shorter the transdermal patch-free interval, the higher the risk that the user does not have a withdrawal bleed and may experience breakthrough bleeding and spotting during the subsequent treatment cycle.</p><p>&nbsp;</p><p>In case of minor skin irritation</p><p>If transdermal patch use results in uncomfortable irritation, a new transdermal patch may be applied to a new location until the next Change Day. Only one transdermal patch should be worn at a time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EVRA® is contraindicated for concomitant use with the medicinal products containing ombitasvir/
paritaprevir/ ritonavir, and dasabuvir, glecaprevir/ pibrentasvir and sofosbuvir/velpatasvir/
voxilaprevir
Combined hormonal contraceptives (CHCs) should not be used in the following conditions. If one of these disorders occurs during the use of EVRA, EVRA must be discontinued immediately. 
●	Presence or risk of venous thromboembolism (VTE) 
●	Venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]); 
●	Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency; 
●	Major surgery with prolonged immobilisation (see section 4.4); 
●	A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4); 
●	Presence or risk of arterial thromboembolism (ATE) 
●	Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris); 
●	Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA); 
●	Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant); 
●	History of migraine with focal neurological symptoms; 
●	A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as: 
-	diabetes mellitus with vascular symptoms 
-	severe hypertension 
-	severe dyslipoproteinaemia 
●	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 
●	Known or suspected carcinoma of the breast 
●	Carcinoma of the endometrium or other known or suspected oestrogen-dependent neoplasia 
●	Abnormal liver function related to acute or chronic hepatocellular disease 
●	Hepatic adenomas or carcinomas 
●	Undiagnosed abnormal genital bleeding 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><strong>Warnings</strong></p><p>During clinical trials with patients treated for hepatitis C virus infections (HCV) with the medicinal<br />products containing ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin,<br />transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred<br />significantly more frequent in women using ethinylestradiol-containing medications such as combined<br />hormonal contraceptives (CHCs). ALT elevations have also been observed with HCV anti-viral<br />medicinal products containing glecaprevir/ pibrentasvir and sofosbuvir/ velpatasvir/ voxilaprevir.</p><p>If any of the conditions/risk factors mentioned below is present, the suitability of EVRA should be discussed with the woman.</p><p>&nbsp;</p><p>In the event of aggravation, or first appearance of any of the conditions or risk factors, the woman should be advised to contact her doctor to determine whether the use of EVRA should be discontinued.</p><p>&nbsp;</p><p>There is no clinical evidence indicating that a transdermal patch is, in any aspect, safer than combined oral contraceptives.</p><p>&nbsp;</p><p>EVRA is not indicated during pregnancy (see section 4.6).</p><p><strong>&nbsp;</strong></p><p><strong>Risk of venous thromboembolism (VTE)</strong></p><p>&nbsp;</p><p>The use of any combined hormonal contraceptive (CHC) increases the risk of venous thromboembolism (VTE) compared with no use. <strong>Products that contain levonorgestrel, norgestimate or norethisterone are associated with the lowest risk of VTE. Other products such as EVRA may have up to twice this level of risk. The decision to use any product other than one with the lowest VTE risk should be taken only after a discussion with the woman to ensure she understands the risk of VTE with EVRA, how her current risk factors influence this risk, and that her VTE risk is highest in the first ever year of use. There is also some evidence that the risk is increased when a CHC is re-started after a break in use of 4 weeks or more.</strong></p><p>&nbsp;</p><p>In women who do not use a CHC and are not pregnant about 2 out of 10,000 will develop a VTE over the period of one year. However, in any individual woman the risk may be far higher, depending on her underlying risk factors (see below).</p><p>&nbsp;</p><p>It is estimated that out of 10,000 women who use a low dose CHC that contains levonorgestrel, about 6<sup><sup>[1]</sup></sup> will develop a VTE in one year. Studies have suggested that the incidence of VTE in women who used EVRA is up to 2-fold higher than in users of CHCs that contain levonorgestrel. This corresponds to between about 6 and 12 VTEs in a year out of 10,000 women who use EVRA.</p><p>&nbsp;</p><p>In both cases, the number of VTEs per year is fewer than the number expected in women during pregnancy or in the postpartum period.</p><p>&nbsp;</p><p>VTE may be fatal in 1-2% of cases.</p><p>&nbsp;</p><p>[1] Mid-point of range of 5-7 per 10,000 WY, based on a relative risk for CHCs containing levonorgestrel versus non-use of approximately 2.3 to 3.6</p><p><img alt="" width="828" height="522" src="data:image/png;base64,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" /></p><p>Extremely rarely, thrombosis has been reported to occur in CHC users in other blood vessels, e.g. hepatic, mesenteric, renal or retinal veins and arteries.</p><p>&nbsp;</p><p><strong>Risk factors for VTE</strong><strong> </strong></p><p>The risk for venous thromboembolic complications in CHC users may increase substantially in a woman with additional risk factors, particularly if there are multiple risk factors (see table).</p><p>&nbsp;</p><p>EVRA is contraindicated if a woman has multiple risk factors that put her at high risk of venous thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase&nbsp;in risk is greater than the sum of the individual factors &ndash; in this case her total risk of VTE should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).</p><p><img alt="" width="693" height="63" src="data:image/png;base64,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" /></p><p><strong>Table: Risk factors for VTE </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><strong>Risk factor </strong></p></td><td style="vertical-align:top"><p><strong>Comment </strong></p></td></tr><tr><td style="vertical-align:top"><p>Obesity (body mass index over 30 kg/m&sup2;)</p></td><td style="vertical-align:top"><p>Risk increases substantially as BMI rises.</p><p>Particularly important to consider if other risk factors also present.</p></td></tr><tr><td style="vertical-align:top"><p>Prolonged immobilisation, major surgery, any surgery to the legs or pelvis,</p><p>neurosurgery, or major trauma</p><p>&nbsp;</p><p>Note: temporary immobilisation including air travel &gt; 4 hours can also be a risk factor for VTE, particularly in women with other risk factors</p></td><td style="vertical-align:top"><p>In these situations it is advisable to discontinue the use of the patch (in the case of elective surgery at least four weeks in advance) and not resume until two weeks after complete remobilisation. Another method of contraception should be used to avoid unintentional pregnancy.</p><p>Antithrombotic treatment should be considered if EVRA has not been discontinued in advance.</p></td></tr><tr><td style="vertical-align:top"><p>Positive family history (venous thromboembolism ever in a sibling or parent at relatively early age)</p></td><td style="vertical-align:top"><p>If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.</p></td></tr><tr><td style="vertical-align:top"><p>Other medical conditions associated with</p><p>VTE</p></td><td style="vertical-align:top"><p>Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn&#39;s disease or ulcerative colitis) and sickle cell disease.</p></td></tr><tr><td style="vertical-align:top"><p>Increasing age</p></td><td style="vertical-align:top"><p>Particularly above 35 years.</p></td></tr></tbody></table><p>&nbsp;</p><p>There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in the onset or progression of venous thrombosis.</p><p>&nbsp;</p><p>The increased risk of thromboembolism in pregnancy, and particularly the 6 week period of the puerperium, must be considered (for information on &quot;Pregnancy and lactation&quot; see section 4.6).</p><p>&nbsp;</p><p><strong>Symptoms of VTE (deep vein thrombosis and pulmonary embolism)</strong><strong> </strong></p><p>In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.</p><p>&nbsp;</p><p>Symptoms of deep vein thrombosis (DVT) can include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unilateral swelling of the leg and/or foot or along a vein in the leg;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or tenderness in the leg which may be felt only when standing or walking; - &nbsp;&nbsp; increased warmth in the affected leg; red or discoloured skin on the leg.</p><p>&nbsp;</p><p>Symptoms of pulmonary embolism (PE) can include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden onset of unexplained shortness of breath or rapid breathing;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden coughing which may associated with haemoptysis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sharp chest pain;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe light headedness or dizziness; - &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid or irregular heartbeat.</p><p>&nbsp;</p><p>Some of these symptoms (e.g. &ldquo;shortness of breath&rdquo;, &ldquo;coughing&rdquo;) are non-specific and might be misinterpreted as more common or less severe events (e.g. respiratory tract infections).</p><p>&nbsp;</p><p>Other signs of vascular occlusion can include: sudden pain, swelling and slight blue discoloration of an extremity.</p><p>&nbsp;</p><p>If the occlusion occurs in the eye symptoms can range from painless blurring of vision which can progress to loss of vision. Sometimes loss of vision can occur almost immediately.</p><p><strong>&nbsp;</strong></p><p><strong>Risk of arterial thromboembolism (ATE) </strong></p><p><strong>&nbsp;</strong></p><p>Epidemiological studies have associated the use of CHCs with an increased risk for arterial thromboembolism (myocardial infarction) or for cerebrovascular accident (e.g. transient ischaemic attack, stroke). Arterial thromboembolic events may be fatal.</p><p>&nbsp;</p><p><strong>Risk factors for ATE</strong><strong> </strong></p><p>The risk of arterial thromboembolic complications or of a cerebrovascular accident in CHC users increases in women with risk factors (see table). EVRA is contraindicated if a woman has one serious or multiple risk factors for ATE that puts her at high risk of arterial thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors - in this case her total risk should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><strong>Table: Risk factors for ATE </strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><strong>Risk factor </strong></p></td><td style="vertical-align:top"><p><strong>Comment </strong></p></td></tr><tr><td style="vertical-align:top"><p>Increasing age</p></td><td style="vertical-align:top"><p>Particularly above 35 years</p></td></tr><tr><td style="vertical-align:top"><p>Smoking</p></td><td style="vertical-align:top"><p>Women should be advised not to smoke if they wish to use a CHC. Women over 35 who continue to smoke should be strongly advised to use a different method of contraception.</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Obesity (body mass index over 30 kg/m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Risk increases substantially as BMI rises.</p><p>Particularly important in women with additional risk factors.</p></td></tr><tr><td style="vertical-align:top"><p>Positive family history (arterial</p><p>thromboembolism ever in a sibling or parent at relatively early age e.g. below 50)</p></td><td style="vertical-align:top"><p>If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.</p></td></tr><tr><td style="vertical-align:top"><p>Migraine</p></td><td style="vertical-align:top"><p>An increase in frequency or severity of migraine during CHC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation.</p></td></tr><tr><td style="vertical-align:top"><p>Other medical conditions associated with adverse vascular events</p></td><td style="vertical-align:top"><p>Diabetes mellitus, hyperhomocysteinaemia, valvular heart disease and atrial fibrillation, dyslipoproteinaemia, systemic lupus erythematosus.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Symptoms of ATE</strong><strong> </strong></p><p>In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.</p><p>&nbsp;</p><p>Symptoms of a cerebrovascular accident can include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden numbness or weakness of the face, arm or leg, especially on one side of the body;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden trouble walking, dizziness, loss of balance or coordination;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden confusion, trouble speaking or understanding;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden trouble seeing in one or both eyes;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden, severe or prolonged headache with no known cause; - &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of consciousness or fainting with or without seizure.</p><p>&nbsp;</p><p>Temporary symptoms suggest the event is a transient ischaemic attack (TIA).</p><p>&nbsp;</p><p>Symptoms of myocardial infarction (MI) can include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest, arm, or below the breastbone;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discomfort radiating to the back, jaw, throat, arm, stomach;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of being full, having indigestion or choking;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating, nausea, vomiting or dizziness; - extreme weakness, anxiety, or shortness of breath; - rapid or irregular heartbeats.</p><p>&nbsp;</p><p>Women using combined contraceptives should be emphatically advised to contact their physician in case of possible symptoms of thrombosis. In case of suspected or confirmed thrombosis, hormonal contraceptive use should be discontinued. Adequate contraception should be initiated because of the teratogenicity of anti-coagulant therapy (coumarins).</p><p>&nbsp;</p><p>Tumours</p><p>An increased risk of cervical cancer in long-term users of COCs has been reported in some epidemiological studies, but there continues to be controversy about the extent to which this finding is attributable to the confounding effects of sexual behaviour and other factors such as human papilloma virus (HPV).</p><p>&nbsp;</p><p>A meta-analysis of 54 epidemiological studies reported that there is a slightly increased risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using COCs. The excess risk gradually disappears during the course of the 10 years after cessation of COC use. Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer. The breast cancers diagnosed in ever-users tend to be less advanced clinically than the cancers diagnosed in never-users. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both.</p><p>&nbsp;</p><p>In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of COCs. In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages. Therefore a hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur in women using EVRA.</p><p>&nbsp;</p><p>Other conditions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contraceptive efficacy may be reduced in women weighing equal or greater than 90 kg (see sections 4.2 and 5.1).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using combined hormonal contraceptives.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Although small increases of blood pressure have been reported in many women using hormonal contraceptives, clinically relevant increases are rare. A definitive relationship between hormonal contraceptive use and clinical hypertension has not been established. If, during the use of combined hormonal contraceptives in pre-existing hypertension, constantly elevated blood pressure values or a significant increase in blood pressure do not respond adequately to antihypertensive treatment, the combined hormonal contraceptive must be withdrawn. Combined hormonal contraceptive use may be resumed if normotensive values can be achieved with antihypertensive therapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following conditions have been reported to occur or deteriorate with both pregnancy and COC use, but the evidence of an association with COC use is inconclusive: Jaundice and/or pruritus related to cholestasis; gallbladder disease including cholecystitis and cholelithiasis; porphyria; systemic lupus erythematosus; haemolytic ureamic syndrome; Sydenham&rsquo;s chorea; herpes gestationis; otosclerosis-related hearing loss.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute or chronic disturbances of liver function may necessitate the discontinuation of combined hormonal contraceptives until markers of liver function return to normal. Recurrence of cholestatic-related pruritus, which occurred during a previous pregnancy or previous use of sex steroids necessitates the discontinuation of combined hormonal contraceptives.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Although combined hormonal contraceptives may have an effect on peripheral insulin resistance and glucose tolerance, there is no evidence for a need to alter the therapeutic regimen in diabetes during use of combined hormonal contraceptives. However, diabetic women should be carefully observed, particularly in the early stage of EVRA use.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of endogenous depression, of epilepsy, of Crohn&rsquo;s disease and of ulcerative colitis has been reported during COC use.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chloasma may occasionally occur with the use of hormonal contraception, especially in users with a history of chloasma gravidarum. Users with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while using EVRA. Chloasma is often not fully reversible.</p><p>&nbsp;</p><p>Medical examination/consultation</p><p>Prior to the initiation or reinstitution of EVRA a complete medical history (including family history) should be taken and pregnancy should be ruled out. Blood pressure should be measured and a physical examination should be performed guided by the contra-indications (see section 4.3) and warnings (see section 4.4). It is important to draw a woman&rsquo;s attention to the information on venous and arterial thrombosis, including the risk of EVRA compared with other CHCs, the symptoms of VTE and ATE, the known risk factors and what to do in the event of a suspected thrombosis.</p><p>&nbsp;</p><p>The woman should also be instructed to carefully read the user leaflet and to adhere to the advice given. The frequency and nature of examinations should be based on established practice guidelines and be adapted to the individual woman.</p><p>&nbsp;</p><p>Women should be advised that hormonal contraceptives do not protect against HIV infections (AIDS) and other sexually transmissible diseases.</p><p>&nbsp;</p><p>Bleeding irregularities</p><p>With all combined hormonal contraceptives, irregular blood loss (spotting or breakthrough bleeding) can occur, especially during the initial months of usage. For this reason, a medical opinion on irregular blood loss will only be useful after an adjustment period of approximately three cycles. If</p><p>breakthrough bleeding persists, or breakthrough bleeding occurs after previously regular cycles, while EVRA has been used according to the recommended regimen, a cause other than EVRA should be considered. Non-hormonal causes should be considered and, if necessary, adequate diagnostic measures taken to rule out organic disease or pregnancy. This may include curettage. In some women withdrawal bleeding may not occur during this transdermal patch free period. If EVRA has been taken according to the directions described in section 4.2, it is unlikely that the woman is pregnant. However, if EVRA has not been taken according to these directions prior to the first missed withdrawal bleed or if two withdrawal bleeds are missed, pregnancy must be ruled out before EVRA use is continued.</p><p>&nbsp;</p><p>Some users may experience amenorrhoea or oligomenorrhoea after discontinuing hormonal contraception, especially when such a condition was pre-existent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Note: The prescribing information of concomitant medicinal products should be consulted to identify potential interactions.</p><p>&nbsp;</p><p>Influence of other medicinal products on EVRA</p><p>Interactions between oral contraceptives and other medicinal products may lead to breakthrough bleeding and/or contraceptive failure. The following interactions have been reported in the literature<strong><em>. </em></strong></p><p>&nbsp;</p><p>Hepatic metabolism</p><p>Interactions can occur with medicinal products that induce hepatic enzymes which can result in increased clearance of sex hormones (e.g. phenobarbital, primidone, rifampicin, rifabutin, bosentan, (fos)aprepitant), some anti-epileptics (e.g. carbamazepine, eslicarbazepine acetate, felbamate, oxcarbazepine, phenytoin, rufinamide, topiramate) and some HIV-medicinal products (e.g. nelfinavir, ritonavir, nevirapine, efavirenz) and possibly also griseofulvin and products containing the herbal remedy St. John&#39;s Wort (<em>Hypericum perforatum</em>).</p><p>&nbsp;</p><p>Maximal enzyme induction is generally seen in about 10 days but may then be sustained for at least 4 weeks after the cessation of medicinal product therapy.</p><p>&nbsp;</p><p>Herbal preparations containing St. John&rsquo;s Wort (<em>Hypericum perforatum</em>) should not be used while taking EVRA.</p><p>&nbsp;</p><p>Interference with enterohepatic circulation</p><p>Contraceptive failures have also been reported with antibiotics, such as penicillins and tetracyclines. The mechanism of this effect has not been elucidated. In a pharmacokinetic interaction study, oral administration of tetracycline hydrochloride, 500 mg four times daily for 3 days prior to and 7 days during wear of EVRA, did not significantly affect the pharmacokinetics of norelgestromin or EE.</p><p>&nbsp;</p><p>Management</p><p>Women on short-term treatment with any of the above-mentioned classes of medicinal products or individual active substances that induce hepatic enzymes (except rifampicin) should temporarily use a barrier method in addition to EVRA, i.e. during the time of concomitant medicinal product administration and for 7 days after their discontinuation. For women on rifampicin a barrier method should be used in addition to EVRA during the time of rifampicin administration and for 28 days after its discontinuation.</p><p>&nbsp;</p><p>In women on long-term treatment with any of the above-mentioned classes of medicinal products, another reliable, non-hormonal, method of contraception is recommended.</p><p>&nbsp;</p><p>Women on treatment with antibiotics (besides rifampicin, see above) should use the barrier method until 7 days after discontinuation.</p><p>&nbsp;</p><p>If concomitant medicinal product administration runs beyond the end of the one-week wear period, the next transdermal patch should be applied without the usual transdermal patch-free interval.</p><p>&nbsp;</p><p>Inhibition of ethinyl estradiol metabolism</p><p>Etoricoxib has been shown to increase plasma levels of ethinyl estradiol (50 to 60%) when taken concomitantly with an oral triphasic hormonal contraceptive. It is thought that etoricoxib increases ethinyl estradiol levels because it inhibits sulfotransferase activity thereby inhibiting ethinyl estradiol metabolism.</p><p>&nbsp;</p><p>Influence of EVRA on other medicinal products</p><p>Hormonal contraceptives may affect the metabolism of certain other active substances. Accordingly, plasma and tissue concentrations may increase (e.g. ciclosporin). Dosage adjustment of the concomitant medicinal product may be necessary.</p><p>&nbsp;</p><p>Lamotrigine: Combined hormonal contraceptives have been shown to significantly decrease plasma concentrations of lamotrigine when coadministered likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary.</p><p>&nbsp;</p><p>Laboratory tests</p><p>The use of contraceptive steroids may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins, e.g. corticosteroid-binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>EVRA is not indicated during pregnancy.</p><p>&nbsp;</p><p>Epidemiological studies indicate no increased risk of birth defects in children born to women who used combined oral contraceptives prior to pregnancy. The majority of recent studies also do not indicate a teratogenic effect when combined oral contraceptives are used inadvertently during early pregnancy.</p><p>&nbsp;</p><p>Limited data on the outcomes of exposed pregnancies in women using EVRA do not allow for conclusions about its safety during pregnancy.</p><p>&nbsp;</p><p>Animal studies have shown undesirable effects during pregnancy and lactation (see section 5.3). Based on these animal data, undesirable effects due to hormonal action of the active compounds cannot be excluded. However, general experience with combined oral contraceptives during pregnancy did not provide evidence for an actual undesirable effect in humans.</p><p>&nbsp;</p><p>If pregnancy occurs during use of EVRA, EVRA should be stopped immediately.</p><p>&nbsp;</p><p>The increased risk of VTE during the postpartum period should be considered when re-starting EVRA (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p>Breast-feeding</p><p>Breast-feeding may be influenced by combined hormonal contraceptives as they may reduce the quantity and change the composition of breast milk. Therefore, the use of EVRA is not to be recommended until the breast-feeding mother has completely weaned her child.</p><p>&nbsp;</p><p>Fertility</p><p>Women may experience a delay in conception following discontinuation of EVRA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EVRA has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<strong> </strong></p><p>The most commonly reported adverse reactions in clinical trials were headache, nausea, and breast tenderness, occurring in approximately 21.0%, 16.6%, and 15.9% of patients, respectively. Adverse reactions that may occur at the beginning of treatment but usually diminish after the first three cycles include spotting, breast tenderness and nausea.</p><p>&nbsp;</p><p>Description of selected adverse reactions</p><p>An increased risk of arterial and venous thrombotic and thrombo-embolic events, including myocardial infarction, stroke, transient ischemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs, which are discussed in more detail in section 4.4.</p><p>&nbsp;</p><p>Tabulated list of adverse reactions</p><p>Safety was evaluated in 3,322 sexually active women who participated in three Phase III clinical trials, which were designed to evaluate contraceptive efficacy. These subjects received six or 13 cycles of contraception (EVRA or oral contraceptive comparator), took at least one dose of study medicinal product and provided safety data. Table 1 below reflects the adverse reactions reported in clinical trials and from post-marketing experience. Frequency MedDRA convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table 1: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency of adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p><strong><em>System Organ Class </em></strong>Frequency</p></td><td style="vertical-align:top"><p><strong>Adverse reaction </strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong><em>Infections and infestations </em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>(Vulvo) vaginal fungal infection</p><p>Vaginal candidiasis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Rash pustular*</p><p>Application site pustules</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Neoplasms benign, malignant and unspecified (incl cysts and polyps) </em></strong></p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>Hepatic neoplasm*&dagger;</p><p>Breast cancer*&dagger; Cervix carcinoma*&dagger;</p><p>Hepatic adenoma*&dagger;</p><p>Uterine leiomyoma</p><p>Fibroadenoma of breast</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Immune system disorders </em></strong></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Metabolism and nutrition disorders </em></strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><!--[if gte vml 1]><v:group id="Group_x0020_36377" o:spid="_x0000_s1028"
   style='position:absolute;margin-left:168.25pt;margin-top:-.1pt;width:.5pt;
   height:76pt;z-index:251658240;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="60,9649" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_40505" o:spid="_x0000_s1029" style='position:absolute;
    width:91;height:6434;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,643433" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,643433l,643433,,e" fillcolor="black" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="83231f" joinstyle="miter"/>
    <v:path arrowok="t" textboxrect="0,0,9144,643433"/>
   </v:shape><v:shape id="Shape_x0020_40506" o:spid="_x0000_s1030" style='position:absolute;
    top:6434;width:91;height:3215;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,321564" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,321564l,321564,,e" fillcolor="black" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="83231f" joinstyle="miter"/>
    <v:path arrowok="t" textboxrect="0,0,9144,321564"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="2" height="102" src="file:///C:/Users/falmajmo/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" />uncommon Hypercholesterolaemia</p><p>Fluid retention</p><p>Increased appetite</p><p>&nbsp;</p><p>rare Hyperglycaemia* Insulin resistance*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Psychiatric disorders</em></strong><em> </em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:bottom"><p>Mood, affect and anxiety disorders</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:bottom"><p>Insomnia</p><p>Libido decreased</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:bottom"><p>Anger*</p><p>Frustration*</p><p>Libido increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Nervous system disorders </em></strong></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:bottom"><p>Headache</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:bottom"><p>Migraine</p><p>Dizziness</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:bottom"><p>Cerebrovascular accident**&dagger;</p><p>Cerebral haemorrhage*&dagger; Abnormal taste*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Eye disorders </em></strong></p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>Contact lens intolerance*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Cardiac disorders </em></strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><!--[if gte vml 1]><v:group id="Group_x0020_36723" o:spid="_x0000_s1026"
   style='position:absolute;margin-left:168.25pt;margin-top:-.1pt;width:.5pt;
   height:25.35pt;z-index:251659264;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="6096,321869" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_40509" o:spid="_x0000_s1027" style='position:absolute;
    width:9144;height:321869;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,321869" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,321869l,321869,,e" fillcolor="black" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="83231f" joinstyle="miter"/>
    <v:path arrowok="t" textboxrect="0,0,9144,321869"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="2" height="34" src="file:///C:/Users/falmajmo/AppData/Local/Temp/2/msohtmlclip1/01/clip_image002.gif" />rare Arterial thromboembolism</p><p>(Acute) myocardial infarction*&dagger;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Vascular disorders </em></strong></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hypertensive crisis*</p><p>Arterial thrombosis**&dagger;</p><p>Venous thrombosis**&dagger;</p><p>Thrombosis*&dagger;</p><p>Venous thromboembolism</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong><em> </em></p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>Pulmonary (artery) thrombosis*&dagger; Pulmonary embolism&dagger;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Gastrointestinal disorders</em></strong><em> </em></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>Nausea</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:bottom"><p>Abdominal pain</p><p>Vomiting</p><p>Diarrhoea</p><p>Abdominal distension</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>rare</p></td><td style="vertical-align:bottom"><p>Colitis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Hepatobiliary disorders</em></strong><em> </em></p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>Cholecystitis</p><p>Cholelithiasis&dagger;</p><p>Hepatic lesion*</p><p>Jaundice cholestatic*&dagger;</p><p>Cholestasis*&dagger;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissue disorders</em></strong><em> </em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>Acne</p><p>Rash</p><p>Pruritus</p><p>Skin reaction</p><p>Skin irritation</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Alopecia</p><p>Dermatitis allergic</p><p>Eczema</p><p>Photosensitivity reaction</p><p>Dermatitis contact</p><p>Urticaria</p><p>Erythema</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Angioedema*</p><p>Erythema (multiforme, nodosum)*</p><p>Chloasma&dagger;</p><p>Exfoliative rash*</p><p>Pruritus generalised</p><p>Rash (erythematous, pruritic)</p><p>Seborrhoeic dermatitis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Musculoskeletal and connective tissue disorders</em></strong><em> </em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Reproductive system and breast disorders</em></strong><em> </em></p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:bottom"><p>Breast tenderness</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td><p>Dysmenorrhoea</p><p>Vaginal bleeding and menstrual disorders**&dagger;</p><p>Uterine spasm</p><p>Breast disorders</p><p>Vaginal discharge</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Galactorrhoea</p><p>Premenstrual syndrome</p><p>Vulvovaginal dryness</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:bottom"><p>Cervical dysplasia*</p><p>Suppressed lactation* Genital discharge</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>General disorders and administration site conditions</em></strong><em> </em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>Malaise</p><p>Fatigue</p><p>Application site reactions (erythema, irritation, pruritus, rash)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>Generalised oedema</p><p>Oedema peripheral</p><p>Application site reactions**</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Face oedema*</p><p>Pitting oedema*</p><p>Swelling</p><p>Application site reactions* (e.g., abscess, erosion) Localised oedema*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Investigations</em></strong><em> </em></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:bottom"><p>Weight increased</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td><p>Blood pressure increased Lipid disorders**</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Blood glucose decreased*&dagger;</p><p>Blood glucose abnormal*&dagger;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* Post-marketing reports.</p><p>** Includes adverse reactions reported in clinical trials and post-marketing reports. &dagger; See section 4.4.</p></td></tr></tbody></table><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:612px"><tbody></tbody><tbody><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Serious ill effects have not been reported following accidental ingestion of large doses of oral contraceptives. Overdose may cause nausea or vomiting. Vaginal bleeding may occur in some females. In cases of suspected overdose, all transdermal contraceptive systems should be removed and symptomatic treatment given.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Sex hormones and modulators of the genital system, progestogens and estrogens, fixed combination; ATC-code: G03AA13.</p><p>&nbsp;</p><p>Mechanism of action</p><p>EVRA acts through the mechanism of gonadotropin suppression by the estrogenic and progestational actions of ethinyl estradiol and norelgestromin. The primary mechanism of action is inhibition of the ovulation, but the alterations of the cervical mucus, and to the endometrium may also contribute to the efficacy of the product.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u> <strong>Pearl Indices (see table): </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:613px"><tbody><tr><td style="vertical-align:top"><p>Study Group</p></td><td style="vertical-align:top"><p>CONT-002 EVRA</p></td><td style="vertical-align:top"><p>CONT-003 EVRA</p></td><td style="vertical-align:top"><p>CONT-003 COC*</p></td><td style="vertical-align:top"><p>CONT-004 EVRA</p></td><td style="vertical-align:top"><p>CONT-004 COC**</p></td><td style="vertical-align:top"><p>All EVRA</p><p>Subjects</p></td></tr><tr><td style="vertical-align:top"><p># of cycles</p></td><td style="vertical-align:top"><p>10,743</p></td><td style="vertical-align:top"><p>5,831</p></td><td style="vertical-align:top"><p>4,592</p></td><td style="vertical-align:top"><p>5,095</p></td><td style="vertical-align:top"><p>4,005</p></td><td style="vertical-align:top"><p>21,669</p></td></tr><tr><td style="vertical-align:top"><p>Overall</p><p>Pearl Index</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>0.73</p><p>(0.15; 1.31)</p></td><td style="vertical-align:top"><p>0.89</p><p>(0.02; 1.76)</p></td><td style="vertical-align:top"><p>0.57</p><p>(0.0; 1.35)</p></td><td style="vertical-align:top"><p>1.28</p><p>(0.16; 2.39)</p></td><td style="vertical-align:top"><p>2.27</p><p>(0.59; 3.96)</p></td><td style="vertical-align:top"><p>0.90</p><p>(0.44; 1.35)</p></td></tr><tr><td style="vertical-align:top"><p>Method</p><p>Failure</p><p>Pearl Index</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>0.61</p><p>(0.0; 1.14)</p></td><td style="vertical-align:top"><p>0.67</p><p>(0.0; 1.42)</p></td><td style="vertical-align:top"><p>0.28</p><p>(0.0; 0.84)</p></td><td style="vertical-align:top"><p>1.02</p><p>(0.02; 2.02)</p></td><td style="vertical-align:top"><p>1.30</p><p>(0.03; 2.57)</p></td><td style="vertical-align:top"><p>0.72</p><p>(0.31; 1.13)</p></td></tr></tbody></table><p>*&nbsp; DSG 150 g + 20 g EE</p><p>** 50 g LNG + 30 g for days 1 &ndash; 6, 75 g LNG + 40 g EE for days 7 &ndash; 11, 125 g LNG + 30 g EE for 12 &ndash; 21 days</p><p>&nbsp;</p><p>Exploratory analyses were performed to determine whether in the Phase III studies (n=3,319) the population characteristics of age, race and weight were associated with pregnancy. The analyses indicated no association of age and race with pregnancy. With respect to weight, 5 of the</p><p>15 pregnancies reported with EVRA were among women with baseline body weight equal or greater than 90 kg, which constituted &lt; 3% of the study population. Below 90 kg there was no association between body weight and pregnancy. Although only 10-20% of the variability in pharmacokinetic data can be explained by weight (see section 5.2), the greater proportions of pregnancies among women at or above 90 kg was statistically significant and indicates the EVRA is less effective in these women.</p><p>&nbsp;</p><p>With the use of higher dosed COCs (50 microgram ethinyl estradiol) the risk of endometrial and ovarian cancer is reduced. Whether this is also applies to the lower dosed combined hormonal contraceptives remains to be confirmed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Following application of EVRA, norelgestromin and ethinyl estradiol levels in serum reach a plateau by approximately 48 hours. Steady state concentrations of norelgestromin and EE during one week of transdermal patch wear are approximately 0.8 ng/ml and 50 pg/ml, respectively. In multiple-dose studies, serum concentrations and AUC for norelgestromin and EE were found to increase only slightly over time when compared to week 1 cycle 1.</p><p>&nbsp;</p><p>The absorption of norelgestromin and ethinyl estradiol following application of EVRA was studied under conditions encountered in a health club (sauna, whirlpool, treadmill and other aerobic exercise) and in a cold water bath. The results indicated that for norelgestromin there were no significant treatment effects on C<sub>ss</sub> or AUC when compared to normal wear. For EE, slight increases were observed due to treadmill and other aerobic exercise; however, the C<sub>ss</sub><sup> </sup>values following these treatments were within the reference range. There was no significant effect of cool water on these parameters.</p><p>&nbsp;</p><p>Results from an EVRA study of extended wear of single contraceptive transdermal patch for 7 days and 10 days indicated that target C<sub>ss</sub> of norelgestromin and ethinyl estradiol were maintained during a 3-day period of extended wear of EVRA (10 days). These findings suggest that clinical efficacy would be maintained even if a scheduled change is missed for as long as 2 full days.</p><p>&nbsp;</p><p>Distribution</p><p>Norelgestromin and norgestrel (a serum metabolite of norelgestromin) are highly bound (&gt; 97%) to serum proteins. Norelgestromin is bound to albumin and not to SHBG, while norgestrel is bound primarily to SHBG, which limits its biological activity. Ethinyl estradiol is extensively bound to serum albumin.</p><p>&nbsp;</p><p>Biotransformation</p><p>Hepatic metabolism of norelgestromin occurs and metabolites include norgestrel, which is largely bound to SHBG, and various hydroxylated and conjugated metabolites. Ethinyl estradiol is also metabolised to various hydroxylated products and their glucuronide and sulfate conjugates.</p><p>&nbsp;</p><p>Elimination</p><p>Following removal of a transdermal patch, the mean elimination half-lives of norelgestromin and ethinyl estradiol were approximately 28 hours and 17 hours, respectively. The metabolites of norelgestromin and ethinyl estradiol are eliminated by renal and faecal pathways.</p><p>&nbsp;</p><p>Transdermal versus oral contraceptives</p><p>The pharmacokinetic profiles of transdermal and oral combined hormonal contraceptives are different and caution should be exercised when making a direct comparison of these PK parameters.</p><p>&nbsp;</p><p>In a study comparing EVRA to an oral contraceptive containing norgestimate (parent drug of norelgestromin) 250 g/ethinyl estradiol 35 g, C<sub>max</sub> values were 2-fold higher for NGMN and EE in subjects administered the oral contraceptive compared to EVRA, while overall exposure (AUC and C<sub>ss</sub>) was comparable in subjects treated with EVRA. Inter-subject variability (%CV) for the PK parameters following delivery from EVRA was higher relative to the variability determined from the oral contraceptive.</p><p>&nbsp;</p><p>Effects of age, body weight, and body surface area</p><p>The effects of age, body weight, and body surface area on the pharmacokinetics of norelgestromin and ethinyl estradiol were evaluated in 230 healthy women from nine pharmacokinetic studies of single 7-day applications of EVRA. For both norelgestromin and EE, increasing age, body weight and body surface area each were associated with slight decreases in C<sub>ss</sub> and AUC values. However, only a small fraction (10&ndash;20%) of the overall variability in the pharmacokinetics of the norelgestromin and EE following application of EVRA may be associated with any or all of the above demographic parameters.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. With respect to the reproductive toxicity norelgestromin showed foetal toxicity in rabbits, but the safety margin for this effect was sufficiently high. Data on reproductive toxicity of the combination of norelgestromin with ethinyl estradiol are not available. Data for combination of norgestimate (precursor of norelgestromin) with ethinyl estradiol indicate for female animals a decrease in fertility and implantation efficiency (rat), an increase in foetal resorption (rat, rabbit) and, with high dosages, a decrease in viability and fertility of female offspring (rat). The relevance of these data for human exposure is unknown as these effects have been seen as related to well-known pharmacodynamic or species-specific actions.</p><p>&nbsp;</p><p>Studies conducted to examine the dermal effect of EVRA indicate this system has no potential to produce sensitisation and results in only mild irritation when applied to rabbits skin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Backing layer</u> low-density pigmented polyethylene outer layer polyester inner layer.</p><p>&nbsp;</p><p>Middle layer</p><p>polyisobutylene/polybutene adhesive crospovidone non-woven polyester fabric lauryl lactate.</p><p>&nbsp;</p><p><u>Third layer</u> polyethylene terephthalate (PET) film polydimethylsiloxane coating.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from light and moisture. Do not refrigerate or freeze.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary packaging material</p><p>A sachet is composed of four layers: a low-density polyethylene film (innermost layer), an aluminium foil, a low-density polyethylene film, and an outer layer of bleached paper.</p><p>&nbsp;</p><p>Secondary packaging material</p><p>Sachets are packaged in a cardboard carton.</p><p>Every carton has 3, 9 or 18 EVRA transdermal patches in individual foil-lined sachets. Sachets are wrapped per three in a transparent perforated plastic film and packed in a cardboard carton.</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patch should be applied immediately upon removal from the protective sachet.</p><p>&nbsp;</p><p>To prevent interference with the adhesive properties of EVRA, no creams, lotions or powders should be applied to the skin area where the EVRA transdermal patch is to be applied.</p><p>&nbsp;</p><p>After use the transdermal patch still contains substantial quantities of active ingredients. Remaining hormonal active ingredients of the transdermal patch may have harmful effects if reaching the aquatic environment. Therefore, the used transdermal patch should be discarded carefully. The disposal label from the outside of the sachet should be peeled open. The used transdermal patch should be placed within the open disposal label so that the sticky surface covers the shaded area on the sachet. The disposal label should then be closed sealing the used transdermal patch within. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Used transdermal patches should not be flushed down the toilet nor placed in liquid waste disposal systems.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JANSSEN-CILAG INTERNATIONAL NV 
Turnhoutseweg, 30 
B-2340 Beerse 
Belgium 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                13 September 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>